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ABSTRACT 
 
CARDIAC EFFECTS OF HUNTINGTON’S DISEASE IN MURINE MODELS 
Daniel D. Child 
Beverly L. Davidson 
Huntington’s disease (HD) is an autosomal dominant disease known for its severe 
neurologic phenotype. However, the causative protein in HD, mutant huntingtin (mHTT), is widely 
expressed across tissue types and may have profound consequences for peripheral organs. 
Notably, heart disease is the second leading cause of death in HD patients, but if or how cardiac 
mHTT expression causes pathology is still unknown. Here, I characterize the cardiac phenotype 
in two HD mouse models and show that dysregulated mTORC1 activity is a key underlying 
mechanism. I show that normal heart growth is limited in HD mouse models, with mass regulated 
independent of systemic changes. Additionally, cardiac mTORC1 activity is decreased in HD 
mice starting at a presymptomatic time point in a manner that requires cardiac mHTT expression. 
The impaired activity results from decreased PI3K/Akt/mTOR signaling at early time points and 
Rheb mislocalization at later disease stages. As a result of mTORC1 dysregulation, HD mice 
have increased mortality, inability to hypertrophy, and increased pathologic changes in response 
to stress. Notably, this phenotype is reversed in HD mice with exogenously activated mTORC1. 
Thus, I propose that mHTT expression in HD hearts dysregulates mTORC1 and leads to 
increased mortality with heart disease. 
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CHAPTER I: INTRODUCTION 
Huntington Disease 
Huntington disease (HD) is a fatal, autosomal dominant neurodegenerative disease 
characterized by a classic triad of uncontrolled movements (chorea), behavioral abnormalities, 
and cognitive decline (1). HD has been recognized as a disorder since at least the middle ages, 
but it was first described thoroughly in the scientific literature in 1872 by the eponymous George 
Huntington, who, significantly, identified its heritable nature (2). The hunt for HD’s genetic etiology 
began in earnest about a century after Huntington’s report, and in 1983, thanks to the cooperation 
of large, affected families in the Lake Maracaibo region of Venezuela, the HD gene locus was 
mapped to chromosome 4p16 (3). Ten years later, IT15 (interesting transcript 15) was identified 
as the HD causal gene (4), the first disease-causing gene discovered through genetic linkage 
analysis (5). IT15 has since been given the more descriptive name huntingtin (HTT). 
HTT spans 10,366 base pairs with 67 exons, encodes the 348 kD protein Huntingtin 
(HTT) (4), and is expressed widely across tissues and organ systems (6-9). HTT”s normal 
function is not well understood, but it has an essential role in development evidenced by 
embryonic lethality in HTT nulliparous mice at day E8.5 (10, 11). Interestingly, mice with neuron-
specific HTT deletion are viable and have normal life span (12), underscoring HTT’s importance 
in early non-CNS tissue. Mechanistically, HTT is predicted to play a scaffolding role in 
intracellular signaling: HTT has been shown to interact with hundreds of different proteins in vivo 
(13), and it is predicted to form an elongated superhelical solenoid structure due to a large 
number of HEAT repeats (14). However, elucidating HTT’s specific mechanisms of action has not 
been a primary focus within the research community because the mutation that causes HD 
imparts gain-of-function toxicity and does not impair HTT’s normal function (15). 
HD is caused by a CAG trinucleotide repeat expansion in HTT exon 1, which produces a 
form of HTT that contains an elongated N-terminal polyglutamine tract (termed mutant HTT, or 
mHTT) (4). mHTT forms intracellular aggregates and disrupts numerous cellular functions, 
including, but not limited to, transcription regulation (16, 17), intracellular transport (18, 19), 
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protein degradation (20, 21), cholesterol homeostasis (22, 23), and mitochondria biogenesis (24, 
25). The mechanistic pathway leading from mHTT expression to cell death is still poorly 
understood, but eventually mHTT expression causes profound neuronal death in the striatum and 
other brain regions (26), leading to the classic HD presentation. CAG tract length determines 
disease: individuals with less than 36 repeats in both HTT alleles are unaffected, those with 36-39 
repeats in at least one allele are at risk (reduced penetrance), and individuals with 40 or higher 
CAG repeats in at least one allele are considered affected (27). Additionally, age at onset 
inversely correlates with CAG tract length (28, 29), and the phenomenon of anticipation—
developing disease symptoms at an age earlier than the previous generation—exists within HD 
families due to progressive expansion of the mutant allele, particularly in the paternal alleles (27). 
Very long CAG triplet repeat tracts can cause HD to manifest in childhood or adolescence and is 
referred to as juvenile HD (30). Regardless of age at onset, death occurs on average 10-15 years 
after symptoms appear (31).  
There is currently no cure for HD, but antisense oligonucleotide (ASO) and adeno-
associated virus (AAV)-mediated gene therapies to reduce HTT levels in the central nervous 
system (CNS) have demonstrated safety and efficacy in animal models and are moving into or 
progressing through clinical trials (32-35). This approach is very promising for treatment of the 
neurologic symptoms, but HD also affects peripheral tissues with high metabolic demand (36-39). 
Thus, CNS-specific therapies may unmask peripheral HD phenotypes and present new clinical 
challenges. 
HD Heart Phenotypes 
An association between HD and the heart has been considered since the late 1980’s. 
Heart disease is one of the leading causes of death in HD patients in both Danish and United 
States populations, second only to pneumonia (40-42). Though these oft-cited statistics are 
interesting, they were compiled from death certificate analyses and their accuracy thus depends 
on the subjective judgement of the people completing the records. They are also unavoidably 
vague about what is meant by “heart disease,” which can take on a myriad of forms. Fortunately, 
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later inquiries into large cardiac disease databases implicated heart failure in 30% of HD patients 
compared to 2% of unaffected age- and sex-matched controls (43-45), providing strong evidence 
in support of the association between HD and heart disease, but still failing to provide insight 
regarding a specific phenotype. One of the rare studies to examine post-mortem HD hearts found 
decreased heart size at autopsy (46), potentially ruling out an HD-associated hypertrophic or 
dilated cardiomyopathy, but the specific heart phenotype occurring in HD is still poorly 
understood. 
Limited studies have concluded that neuronal heart regulation is affected in HD, possibly 
leading to heart disease. In a survey of systemic HD signs and symptoms, both pre-manifest and 
symptomatic HD patients reported increased frequency of autonomic abnormalities including 
gastrointestinal, genitourinary, and cardiovascular problems such as lightheadedness on standing 
relative to age- and sex-matched controls (47). Accordingly, the few clinical studies that have 
examined the heart in HD patients largely focused on autonomic nervous system (ANS) 
regulation and employed noninvasive, autonomic function analysis tools—sympathetic skin 
response, heart rate variability (HRV) measures, and blood pressure changes. Early studies 
found that the balance between parasympathetic and sympathetic branches of the ANS is 
affected in HD patients and worsens with disease progression, and suggested that sympathetic 
activity was favored in HD patients (48, 49). A more sensitive analysis of HRV and blood pressure 
changes under various challenges in pre-manifest and early-stage HD patients concluded that 
increased sympathetic tone was secondary to parasympathetic dysfunction (50). These 
conclusions were supported by a later study that observed decreases in HRV measurements on 
head-up tilt that specifically represent impaired cardiovagal regulation (51).  
One of the hypotheses stemming from these findings is that the dysautonomia leading to 
augmented sympathetic activity in HD patients may predispose to fatal arrhythmias, thereby 
explaining the heart disease-related mortality (48, 51). Indeed, decreased parasympathetic tone 
is considered to be pro-arrhythmic (52) and predisposes to sudden cardiac death even in healthy 
subjects (53, 54). However, history of arrhythmia—or any other form of heart disease—is one of 
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the exclusion criteria for many HD-related clinical studies (44), thus introducing a selection bias 
into many reports. At the time of writing this dissertation, only one study has been reported 
specifically looking for conduction abnormalities in HD patients: electrocardiograms in 538 early-
stage HD patients found increased rates of bradycardia and prolonged intraventricular 
conduction, which could lower the threshold for arrhythmias and accelerate other heart 
pathologies (55). These findings are especially interesting given the data supporting impaired 
parasympathetic activity—which usually causes tachycardia—and suggest that both heart-
specific and neuronal abnormalities occur in HD patients. While these studies show altered ANS 
regulation of the heart in HD, they tend to be limited by small sample sizes and the accuracy of 
HRV measurements (56). Thus, while HD patients may indeed experience ANS abnormalities, 
the functional consequences remain unknown. 
There have been no studies to date examining functional or molecular cardiac 
parameters in HD. This gap in knowledge exists partially because of limited resources: heart and 
other peripheral tissues are not routinely collected for banking, and parameters related to 
cardiovascular health are not included in any of the large HD patient observational studies and 
databases, including PREDICT-HD, TRACK-HD, REGISTRY, and Enroll-HD (57-59). Considering 
heart disease is common in the general population, fully characterizing the HD heart phenotype 
will likely require a relatively large sample size drawn from multiple patient populations. 
HD Animal Models 
While the HD cardiac phenotype has not been well-characterized in humans, the heart in 
HD animal models have been more thoroughly investigated. One of the primary challenges in 
modelling HD in flies or mice is timing: the average CAG repeat number in HD patients (~42) 
does not manifest disease for several decades, and therefore repeat lengths of this size do not 
affect shorter-lived species. Inducing a phenotype in animal models requires the CAG repeat 
number to be significantly increased and/or the toxic product to be expressed at high levels. 
Thus, genetic animal models for HD fall into one of three categories: transgenic fragment, 
transgenic full-length, and knock-in models. 
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Transgenic fragment models 
Transgenic fragment models are designed based on the observation that neuronal 
inclusion bodies in post-mortem HD brain samples contain high amounts of N-terminal mHTT 
cleavage products, suggesting that a mHTT fragment containing the expanded polyglutamine 
(polyQ) tract is sufficient to induce toxicity (60, 61). Indeed, mHTT N-terminal fragments are more 
cytotoxic than full-length mHTT in experimental systems (62), and transgenic mHTT fragment 
models recapitulate HD-like neurologic and metabolic phenotypes (63-66). Given the relative 
ease of working with a smaller fragment compared to full-length HTT, numerous transgenic 
models have been made for HD research. The expressed fragment in these models can range in 
size from a long polyQ peptide (67, 68) to several N-terminal mHTT exons (64). The most 
commonly used HD transgenic fragment model is the R6/2 mouse, which generally express HTT 
exon 1 with 141-157 CAG repeats from the human HTT promoter. However, the mouse threshold 
for CAG tract instability seems to be around 100 repeats (69-71), so the R6/2 mouse is prone to 
spontaneous expansion and contraction. Indeed, unintended R6/2 sublines exist with ≥350 
repeats (72). The typical R6/2 phenotype is a rapid and severe disease, with motor symptoms 
onset at approximately 8 weeks of age and life expectancy between 12-15 weeks (65, 66). The 
N171-82Q mouse is an alternative transgenic fragment model that addresses many of the 
problems associated with the R6/2 mouse: hemizygotes express HTT exons 1-3 with a more 
stable 82-residue polyQ tract from a prion promoter, develop motor symptoms at around 10 
weeks of age, and have a life expectancy of 24 weeks (64). The genetic landscape in these 
models differs considerably from that of HD patients, but they have proved extremely useful in 
elucidating pathogenic HD molecular mechanisms and developing novel treatment strategies. 
Transgenic full-length HTT models 
The difficulty associated with creating transgenic full-length HTT models was solved 
using yeast or bacterial artificial chromosomes (YAC or BAC, respectively) (73, 74). Mice created 
from both artificial construct types utilize multiple transgene copy number and high CAG triplet 
repeat number to induce a phenotype (100 and 126 in the most common YAC model, YAC128; 
97 in the BAC model, BACHD), but the presence of the full-length gene imparts higher construct 
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validity than transgenic fragment models (73, 74). Additionally, both models contain a small 
number of CAA repeats interspersed throughout the CAG tract that prevents both germline and 
somatic expansion but still encodes glutamine. However, disease in these mice is more insidious 
and they typically do not experience shortened lifespan, making them less convenient for 
experimental purposes (75). Additionally, both YAC128 and BACHD mice gain weight over their 
lifespans, opposite the weight loss phenotype observed in patients and other HD mouse models, 
which makes these models inappropriate for studying systemic phenotypes (76, 77). This 
unexpected phenotype correlates with human HTT gene copy in mice—suggesting that human 
HTT has slightly different function than the endogenous mouse huntingtin homologue, Hdh—and 
may result from IGF1 signaling activation in full-length transgenic mice (77, 78). Nevertheless, 
these models have proved especially useful for studying potential therapies targeting the human 
HTT gene or protein. 
Knock-in models 
HD knock-in (KI) models contain a CAG repeat expansion in one or both of the 
endogenous mouse HTT alleles, thereby recapitulating HD genetics better than either of the 
transgenic models. Expanding the HTT allele in KI models occurs through homologous 
recombination, eliminating the confounding factors associated with random transgene integration 
and making possible allelic series of mice that differ only in CAG repeat number. As with other 
HD mice, though, shorter CAG repeat tracts do not produce robust phenotypes, and many 
studies therefore rely on mice with CAG tracts longer than the most expanded human alleles (28, 
29). With knock-in lines it is also possible to study mice either heterozygous or homozygous for 
the expanded allele; homozygotes tend to have more robust and easily-detectable phenotypes, 
but very few HD patients have two mutant alleles, so heterozygous KI mice better replicate the 
typical human genetics (79). The phenotypes in the commonly-used heterozygous KI lines 
HdhQ150 and zQ175 are insidious onset, slow progression, and no decrease in life expectancy 
(80, 81). These mice are the most accurate of all available mouse models, but the relatively mild 
phenotype requires large study numbers and thus limits their experimental utility. 
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Heart Phenotypes in HD Models 
Evidence of heart pathology has been detected in many HD models, though the 
mechanisms leading to the phenotypes are not well understood. Heart disease can occur as a 
result of intrinsic cardiac abnormalities, abnormal autonomic inputs, and pathology in other 
peripheral organs such as the blood vessels, liver, or kidney (82). Consequently, one of the 
outstanding questions in studies of HD animal model hearts is which of those etiologies explains 
the observations. One of the simplest models studied was a Drosophila melanogaster engineered 
to express cardiac-specific polyglutamine (polyQ) peptides containing either 25 (non-pathogenic 
control), 46, 72, of 102 residues. Flies expressing the expanded peptides experienced dose-
dependent functional pathology of dilated chambers, impaired contractility, arrhythmias, and 
reduced survival (67). Additionally, on closer inspection the expanded polyQ fly hearts showed 
dose-dependent disorganization of myofibrillar structure, mitochondrial pathology, and increased 
oxidative stress (67). Similarly, heart-specific expression of an 83-residue polyQ peptide in mice 
resulted in dilated ventricles, cardiomyocyte necrosis, inflammation, fibrosis, and decreased 
survival compared to mice expressing a 19-residue peptide (68). Though the phenotype 
associated with polyQ peptide overexpression likely models amyloidosis better than HD, these 
systems suggest that cardiac mHTT expression may cause cardiomyopathy independent of 
neuronal or systemic insults. 
Though polyQ expression within cardiomyocytes may cause toxicity, studies in more 
accurate HD mouse models have presented a more nuanced phenotype. The first study to 
examine the heart phenotype in R6/2 mice found diminished size, ventricular wall motion, and 
passive ventricular filling, (37). Ultrastructural mitochondrial morphology was also altered, and 
though the left ventricles were mildly dilated at necropsy, there was no evidence of fibrosis or 
apoptosis at end-stage disease (37). However, later studies have found evidence of mild, 
progressive fibrosis in R6/2, homozygous HdhQ150 knock-in (83), Q175 knock-in (84), and 
BACHD mice (85). Cardiac MRI studies in the R6/2 mouse confirmed general decreased heart 
size in the HD mice, and also found that heart shape gets progressively more distorted and 
ventricles become weaker and stiffer than in wild type (WT) littermates (86). Additionally, 
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diminished coronary blood flow rate in R6/2 mouse hearts indicates decreased coronary reserve 
and increased susceptibility to ischemic injury (86). On a molecular level, R6/2 and HdhQ175 
showed increased expression of fetal and pathology-associated genes, together indicative of 
ongoing heart pathology (83), and BACHD mouse hearts have increased levels of pro-apoptotic 
proteins (85). While certain phenotypic details differ both between mouse lines and between 
studies, it is clear that the heart is affected in multiple HD mouse models. 
The mechanisms leading to heart abnormalities have been less obvious in HD mouse 
models. Similar to HD patients, many studies have implicated autonomic dysfunction as central to 
the phenotype. Examination of myocardial electrical activity in the R6/2 and HdhQ150 mouse 
indicated heart rate (HR) was slower but more variable in both HD models compared to WT 
littermates, with elongated QT, ST, and QTS intervals, suggesting possible long QT syndrome 
(83). On histology, the R6/2 and HdhQ150 mice also showed markedly altered ganglionic plexus 
structure within the myocardium, and mislocalization of the gap junction protein Connexin 43, 
supporting the hypothesis that neural regulation and myocardial conduction are impaired in HD 
(83). Weighted gene correlation network analysis in these two models at end-stage disease 
suggested that an HD-related global transcriptional dysregulation does not occur in cardiac 
tissue, attributing heart pathology to altered neuronal or other systemic inputs (83). The Q175 KI 
model also displayed severe autonomic dysfunction, with decreased heart rate variability and 
altered circadian rhythms in both heterozygous and homozygous mice, and blunted baroreceptor 
response in homozygotes (84). These studies thus confirm autonomic impairment as a factor in 
HD, but it is still unclear how altered neuronal regulation contributes to the observed heart 
pathology. 
Aberrant autonomic heart regulation can result from both CNS degeneration and 
cardiomyocyte-specific pathology, and evidence suggests that mHTT expression in HD mouse 
models causes cell-autonomous pathology independent of neural inputs. Specifically, chronic 
exposure to the β-adrenergic agonist isoprenaline (ISO) failed to induce heart hypertrophy in 
R6/2 mice and increased heart failure-associated gene expression (87). Similar ISO exposure in 
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BACHD mice causes significantly greater fibrosis than in stressed WT littermates, suggesting that 
cardiac mHTT expression sensitizes the heart to stress (85). Additionally, the transcription 
profiles of 18 histone deacetylases (HDAC) and sirtuins differed significantly between stressed 
R6/2 and WT mice hearts (87). These epigenetic modifiers have key roles in directing the cardiac 
hypertrophic response (88-90), and their blunted expression indicates that hypertrophic signaling 
is impaired in HD hearts. The mechanisms underlying abnormal stress response are still unclear, 
but because ISO acts directly on cardiomyocytes independent of neuronal inputs the effect is 
likely linked to mHTT expression in the heart.  
One of the factors contributing to the abnormal stress phenotype may be mitochondrial 
dysfunction. The ultrastructural mitochondrial morphology in R6/2 mouse hearts was significantly 
more circular and less ellipsoid than in WT littermates (37). Additionally, deregulated 
mitochondria-associated genes were identified in RNA-seq or microarray analyses of R6/2 (87) 
and BACHD (85) hearts, respectively. A detailed metabolic study in R6/2 and homozygous 
HdhQ150 mouse hearts found decreased ATP/ADP and NADH/NAD+ ratios, with diminished 
phosphocreatine levels, accompanied by elevated purine catabolites—including hypoxanthine, 
uric acid, and uridine—in serum from both HD mice and patient samples (91). Metabolic labelling 
in HD mouse hearts demonstrated normal glycolysis but impaired Krebs cycle flux, concluding 
that mitochondrial dysfunction in HD hearts impairs ATP generation and leads to accumulation of 
nucleotide catabolites in serum (91). These bioenergetics abnormalities within HD murine model 
hearts are similar to those observed in heart failure (92, 93), so it is difficult to ascertain whether 
these changes are a cause or a consequence of the HD animal heart pathology. Nevertheless, 
the HD hearts have a clearly diminished energy reserve, which could sensitize hearts to stress 
and lead to a unique cardiomyopathy. 
Significance and Focus of Dissertation 
Clinical evidence indicates that heart disease is one of the leading causes of mortality in 
HD patients (40-45). Given the profound neurodegeneration that occurs in HD, clinical studies 
have largely focused on neuronal regulation of the heart and found significant dysautonomia (48-
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51), which is recapitulated in HD animal models (83, 84). While altered neuronal control can 
adversely affect the heart, preclinical studies have also suggested that mHTT expression within 
cardiomyocytes may also contribute to heart abnormalities and lead to a unique form of 
cardiomyopathy that includes small heart size, progressive contractile impairment with fibrosis, 
and inability to adapt to stress (83-87). The contribution of cardiac mHTT to the heart phenotype 
in HD thus remains largely unknown. Additionally, the heart phenotype has been examined on a 
functional and tissue level for multiple HD animal models, but very few studies have proposed 
underlying molecular mechanisms. Elucidating the pathogenic processes that occur in HD hearts 
will inform clinical care to decrease heart-related mortality and improve quality of life for HD 
patients. Finally, CNS-directed mHTT-lowering approaches will likely unmask heart phenotypes, 
so understanding the cellular mechanisms that contribute to HD heart pathology will be essential 
for directing future therapeutic strategies. 
In this dissertation, I focus on understanding how cardiac molecular changes in HD lead 
to heart-related mortality. I characterize the heart phenotype in two HD mouse models and 
propose that cardiac mHTT expression impairs mTORC1 activity, resulting in decreased ability to 
adapt to cardiac stress. In Chapter II, I characterize the heart phenotype in the N171-82Q and 
heterozygous zQ175 HD mouse models and find that HD mouse hearts have diminished size but 
are otherwise functionally normal, suggesting that mHTT expression alone may not be sufficient 
to cause heart disease. In Chapter III, I describe diminished mTORC1 activity in HD mouse 
hearts, examine the upstream effectors to illuminate the underlying mechanism, and show that 
mHTT expression is necessary for mTORC1 dysregulation. In Chapter IV, I show that restoring 
mTORC1 activity can alleviate the sensitivity to cardiac stress in HD hearts. Chapter V provides a 
summary of the results and discusses implications and future considerations. 
Contributions to work presented in this Thesis 
This thesis represents work that was, in part, submitted for publication in Cell Reports, 
which has been accepted based on reviewer comments. Work contributed by authors other than 
DC is indicated in the methods or figure legends. 
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CHAPTER 2: CARDIAC PHENOTYPE IN HD MOUSE MODELS 
Introduction 
CNS-specific HTT-lowering therapies, currently entering or progressing through clinical 
trials (32-35), may unmask peripheral phenotypes and present new clinical challenges. HD 
patients have relatively high mortality (40-42) of heart disease, but the phenotype in HD patients 
is poorly understood for numerous reasons, including a justified focus on the brain, history of 
heart disease as an exclusion factor in clinical studies, and limited peripheral tissue collection. 
Thus, most of our understanding of an HD heart phenotype is inferred from animal models, 
particularly mice. 
Efforts to characterize the heart phenotype in HD mice have shown variability between 
different models and among different studies using the same model. The challenges associated 
with each mouse used must be considered when interpreting results. For example, the R6/2 
mouse has been studied more than any other model, but its aggressive metabolic and systemic 
phenotypes may confound heart studies (66). The BACHD mouse has better model validity than 
transgenic fragment models, but becomes obese with age, thereby displaying the opposite 
metabolic phenotype as HD patients (76). Obesity has very well-studied adverse consequences 
for the heart (94) and therefore significantly confounds any comparison between hemizygotes 
and WT littermates. KI models are likely the most valid HD animal model, but even the most 
expanded CAG lines develop the disease slowly and tend to have subtle phenotypes. 
Consequently, most heart studies that employ these models used animals homozygous for the 
expanded allele, which are more severely affected than heterozygotes but replicate a genetic 
landscape uncommon in the HD population. 
For my studies, I used two HD mouse models with previously unstudied heart 
phenotypes in order to minimize confounding factors and enable the use of previously validated 
tools. The majority of my work was done in the N171-82Q model, a transgenic fragment model, 
with findings validated in heterozygous zQ175 mice, a knock-in model. The N171-82Q strain has 
numerous benefits over the R6/2 mouse including a CAG tract nearly half the length, thereby 
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imparting greater generation-to-generation stability and more similar to the human mutation 
(though still considerably longer than the average HD patient) (69). Additionally, the phenotype in 
N171-82Q mice is less severe than in R6/2 mice but still robustly recapitulates the HD neurologic 
and systemic signs (64). Finally, the transgenic fragment in N171-82Q mice is longer than the 
fragment expressed by R6/2 mice and therefore contains sequences targeted by validated, 
artificial microRNAs (miRNA) to knock down (KD) mHTT, a tool employed in later chapters. 
Though useful for experimental purposes, the transgenic nature of N171-82Q means that two 
normal mouse Htt alleles are present, so I validated my results in heterozygous zQ175 mice. 
I performed a thorough examination of the heart in each mouse model, starting from an in 
vivo functional approach and working down to a molecular level, to both better understand the 
individual strain phenotypes and to broaden understanding of the HD phenotype. I hypothesized 
that, similar to other HD mouse models, hearts would be smaller than in WT littermates. Given 
previous results from the R6/2 and HdhQ150 model, I expected to observe progressive 
indications of heart failure including fibrosis, apoptosis, and activation of a heart failure-
associated gene expression profile. 
Results 
Cardiac function is normal in HD mouse hearts 
Progressive cardiac function and morphology abnormalities have been described in HD 
mouse models, though with variation between models. The R6/2 model had decreased cardiac 
output secondary to diminished stroke volume and fractional shortening on echocardiogram, as 
well as altered ventricular filling dynamics on ex vivo analyses, together indicative of stiff, weak 
ventricles (37, 86). Conversely, MRI found smaller heart size in homozygous HdhQ150 but 
recorded normal ejection fraction, suggesting normal function but smaller heart size (83).  
I determined where 18 week-old N171-82Q (end-stage disease) and 18 month-old 
heterozygous zQ175 (symptomatic) mice fit on this functional spectrum by transthoracic 
echocardiography. In N171-82Q mice, left ventricular end diastolic (LVEDV, Figure 1A) and 
systolic volumes (LVESV, Figure 1B) were decreased, as was estimated left ventricular mass 
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(LV mass, Figure 1C) and heart rate (HR, Figure 1D) relative to WT littermates. 
Correspondingly, the calculated stroke volume (SV, Figure 1E) and cardiac output (CO, Figure 
1F) were also reduced. However, ejection fraction (EF, Figure 1G) and fractional shortening (FS, 
Figure 1H) were increased at baseline in transgenic animals relative to WT, suggesting these HD 
mice have smaller hearts than their WT littermates but maintain intact ventricular function at end-
stage disease. zQ715 mice had similar but less pronounced differences as N171-82Q animals. In 
the KI mice, LVEDV (Figure 2A) and LVESV (Figure 2B) were decreased, as was estimated LV 
mass (Figure 2C). There were no differences in HR (Figure 2D), SV (Figure 2E), CO (Figure 
2F), EF (Figure 2G), or FS (Figure 2H). Both HD mouse models thus appear to have diminished 
heart size, but EF and FS—general indicators of heart function—are either increased or equal to 
WT, suggesting that hearts in these models are not functionally impaired.  
HD mouse hearts have decreased gross size compared to WT 
Diminished cardiac mass has been reported in multiple mouse models (37, 84, 86) and in 
human HD patients at autopsy (46), suggesting that it is a key aspect of the HD heart phenotype. 
I confirmed echocardiography measurements by gross examination of HD mouse hearts and 
followed changes over time. Excised hearts from N171-82Q mice at end-stage disease were 
visibly smaller than their WT littermates but had no apparent morphologic differences such as 
ventricular dilation (Figure 3A). When tracked temporally, decreased heart mass in HD relative to 
WT mice became apparent at 10 weeks (early-stage disease) and continued to manifest 
throughout the study (Figure 3B). The growth curves show that the differences between HD and 
WT heart masses result from failure to gain mass around the time of symptom onset, a trend 
consistent with the reported pattern of body mass changes in HD patient populations (95). 
I normalized heart masses to both tibia length and body mass in order to determine if size 
discrepancies between N171-82Q and WT hearts were intrinsic or due to systemic conditions. If 
heart mass differences result from lack of growth factors, the tibia length will be decreased and 
heart mass to tibia length ratio will be equal between genotypes. Tibia lengths were identical 
between HD and WT animals at every time point observed (Figure 4A), and thus heart mass to 
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tibia length was decreased starting at 10 weeks and continuing through disease (Figure 4B). 
Accordingly, heart growth impairment in N171-82Q animals is not secondary to a lack of growth 
factors. 
Decreased body mass is common in both HD patients and mouse models, so decreased 
heart mass may simply result from negative systemic energy balance. I found reduced body mass 
N171-82Q mice, starting before symptom onset and continuing through disease (Figure 5A). 
Interestingly, the heart mass-to-body mass ratio does not differ between WT and N171-82Q 
animals at 6 weeks (pre-symptomatic) and 10 weeks of age (early-stage disease), but at 14 
weeks (mid-stage disease) and 18 weeks of age it is larger in N171-82Q animals relative to WT, 
suggesting that the heart mass does not change proportionally with the rest of the body (Figure 
5B). Indeed, comparing heart mass and body mass in N171-82Q mice over lifespan shows 
relatively constant heart mass while body mass fluctuates (Figure 5C). While it is not possible to 
rule out negative energy balance affecting the heart at early time points, the later growth curve 
differences suggest that HD mouse heart mass is regulated independent of body mass changes. 
Heart mass differences were similar in zQ175 animals at 12 months of age (post 
symptomatic). Both heart mass (Figure 6A) and heart mass-to-tibia length ratio (Figure 6B) are 
decreased in HD mice relative to WT, with no change in tibia length between genotypes (Figure 
6C), confirming conclusions from observations of N171-82Q mouse hearts. Additionally, body 
mass was decreased in 12 month-old zQ175 animals (Figure 7A), but there was no difference in 
heart mass-to-body mass ratio (Figure 7B), implying that at 12 months zQ175 hearts are still 
proportionate to body mass at this time point.  
HD mouse cardiomyocyte size is decreased 
Based on the observation that HD mouse hearts have limited growth but don’t atrophy 
over the course of disease, I hypothesized that HD mouse hearts would have decreased 
cardiomyocyte size relative to WT rather than cell loss. I measured cardiomyocyte cross-sectional 
area using wheat germ agglutinin staining to identify cardiomyocyte borders (Figure 8A). As 
expected, there was no difference in mean cross-sectional area in 6-week-old N171-82Q mice 
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relative to WT littermates, but 14-week-old N171-82Q mice and 12-month-old zQ175 mice had 
decreased myocardial cross-sectional area relative to WT (Figure 8B-C). These results were 
further supported by examining surface area of ex vivo cardiomyocytes isolated from 14 week-old 
N171-82Q hearts, which showed smaller surface area than age-matched WT cardiomyocytes 
(Figure 9). Based on these data, the size difference between HD and WT hearts appears to 
result from reduced cardiomyocyte size. 
Loss of cardiomyocytes in HD hearts relative to WT may contribute to gross size 
differences, and both the R6/2 and BACHD mouse model have progressive, mild fibrosis, 
indicative of cardiomyocyte death (83, 85). In order to determine if similar effects occur in N171-
82Q and zQ175 hearts, I stained heart sections with Masson’s trichrome but found no evidence of 
fibrosis in HD hearts from N171-82Q mice at 6 or 14 weeks of age, or in zQ175 animals at 12 
months of age (Figure 10). Additionally, TUNEL staining of 18 week N171-82Q hearts showed no 
evidence of apoptosis (Figure 11). Together, these data denote limited cardiomyocyte growth in 
HD models accounting for mass differences, not cardiomyocyte loss. 
Metabolic changes in HD mice do not explain decreased body mass 
Heart and whole body growth curves are different for N171-82Q mice, suggesting that 
heart size is regulated independent of body mass (Figure 5C). However, a systemic negative 
energy balance—expending more calories than are consumed—may underlie impaired heart 
growth. I therefore investigated the body mass phenotype in HD mice on a systems level in order 
to identify possible etiologies that could underlie the inhibited heart growth. HD patients and 
mouse models have been described as hypermetabolic, losing body weight especially at end 
stage disease (96). I used a comprehensive laboratory animal monitoring system (CLAMS) to 
analyze metabolic function in HD mice. I examined N171-82Q mice and WT littermates at 9, 13, 
and 17 weeks of age, and zQ175 and WT littermates at 12 months of age, and assessed oxygen 
consumption (VO2), carbon dioxide production (VCO2), feeding, and activity over the course of 72 
hours. Due to circadian regulation of metabolism, I also stratified data into light and dark cycles. 
Surprisingly, I found that N171-82Q mice at 13 and 17 weeks of age had lower VO2 and VCO2 
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during the light cycle than WT littermates, with no differences during the dark cycle (Figure 12A-
B), indicating a hypometabolic state during the day. Additionally, N171-82Q were more active 
than WT littermates during the light cycle at all time points tested and also during the dark cycle 
at 13 and 17 weeks of age (Figure 12C). Feeding patterns were altered in 13 and 17 week-old 
N171-82Q mice relative to WT, with no difference in total food consumed per day but altered 
timing: HD mice ate less during the light cycle but more during the dark cycle (Figure 12D). 
Together, N171-82Q mice had a lower metabolic rate than WT littermates in spite of increased 
activity, suggesting that decreased body mass and limited heart growth is not a result of systemic 
negative energy balance. However, ambient room temperature was measured to be 18°C 
(compared to 22°C normal housing), which may confounded results. 
Metabolic measurements in 12 month-old zQ175 mice were similar to those from N171-
82Q mice. VO2 and VCO2 were decreased during the light cycle compared to WT littermates, with 
no difference during the dark cycle (Figure 13A-B). Activity in zQ175 mice was increased relative 
to WT during the light cycle, with a similar trending but non-significant increase during the dark 
cycle (Figure 13C). Additionally, zQ175 mice food intake trended lower during the light cycle but 
was not statistically significant (Figure 13D). While these data recapitulate, in many respects, the 
data from N171-82Q mice, the ambient room temperature again was lower than normal housing 
rooms and thus should be interpreted cautiously. 
Gene expression in HD mice does not indicate ongoing heart pathology  
I did not observe functional impairment on echocardiography (Figure 1), but gene 
signatures associated with heart failure have been detected in other HD mouse model hearts (83, 
85). Typically, these genes sense stress and limit maladaptive changes. Atrial natriuretic peptide 
(Anp) and brain natriuretic peptide (Bnp) are hormones expressed in the ventricles (despite their 
names) that reduce central venous pressure in response to excessive cardiomyocyte stretching 
(97). Anp and Bnp expression were both decreased at 14 and 18 weeks in N171-82Q animals—
opposite the expected findings in cases of heart failure—and BNP expression was also 
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decreased at 6 weeks in N171-82Q mice (Figure 14A-B). No differences were observed between 
zQ175 and WT hearts at 12 months.  
Another set of genes associated with cardiac stress are Fhl1 and Fh2, members of the 
Four-and-a-Half-LIM Domain family that are involved in myogenesis, stress sensing, and cardiac 
hypertrophy. They are typically expressed only in fetal hearts but are upregulated in cases of 
heart failure (98, 99). In N171-82Q hearts, Fhl1 was slightly increased relative to WT at 6 weeks 
of age (Figure 15A), though the increase is less than the levels observed in heart failure. 
Furthermore, both Fhl1 and Fhl2 were decreased relative to WT at 14 weeks in N171-82Q hearts, 
and no differences were observed at either 18 weeks or in 12 month zQ175 animals (Figure 15A-
B). Together with natriuretic protein expression, these results corroborate the echocardiography 
results (Figure 1) and confirm that N171-82Q and zQ175 mice are not experiencing increased 
stress.  
Although cardiomyocyte apoptosis was not evident by TUNEL staining at 18 weeks 
(Figure 11), I queried transcripts encoding the apoptotic factors Bax (pro-apoptotic) and Bcl2 
(anti-apoptotic) as a more sensitive indicator. Bax levels were modestly increased in in N171-82Q 
hearts relative to WT at 6 and 10 weeks, but were decreased at 14 weeks and not different from 
WT at 18 weeks. Thus apoptosis may be mildly activated at early disease stages but not at later 
stages (Figure 16A). Additionally, Bax expression in heart failure is typically increased by 
multiple fold, whereas the increase observed here is relatively small (100). There were no Bax 
differences in zQ175 hearts relative to WT (Figure 16A), nor were there differences in Bcl2 
expression at any time point in either mouse model (Figure 16B). These data thus reaffirm the 
TUNEL analysis and indicate that apoptosis is only occurring at specific time points and at low 
levels, if it is indeed occurring at all. 
Finally, I examined general expression markers of heart pathology. Vgl4 and S100a4 are 
typically increased in heart disease (101-103), and Serca2a tends to be decreased in unhealthy 
hearts (104); these genes also have altered expression in the R6/2 and Q150 HD mouse models 
(83). Vgl4 expression was increased at 10 weeks in N171-82Q hearts and 12 month zQ175 
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hearts relative to WT, but decreased at 14 weeks and no change at 18 weeks in N171-82Q 
hearts (Figure 17A). Additionally S100a4 expression was increased in 6 week and 10 week 
N171-82Q hearts relative to WT, with no difference at later stages or in zQ175 hearts (Figure 
17B). Serca2a expression did not differ between HD and WT at any time point in either model 
(Figure 17C). These expression patterns suggest different disease processes between early and 
late disease stages. However, as with other genes analyzed, the modest increase in Vgl4 and 
S100a4 expression in HD model hearts are much less than those observed in heart failure. Thus, 
taken together these data infer that HD does not necessarily cause heart failure. 
Discussion 
Heart failure phenotypes have been observed in several HD mouse models (37, 83, 85), 
suggesting that mHTT expression in the brain or heart causes cardiac disease. In my studies I 
found evidence to suggest that mHTT expression in two HD murine models, N171-82Q and 
zQ175, is associated with smaller heart size but may not directly cause pathology. 
Echocardiography analysis showed that HD hearts were smaller than WT littermates, but normal 
or increased EF and FS indicated lack of functional impairment. Gross analysis similarly showed 
diminished size in HD hearts, but no morphologic abnormalities to suggest ongoing pathology. 
Furthermore, heart mass appears to be regulated independent of body mass. On histology, cell 
area was decreased in HD hearts relative to WT, but there was no fibrosis or apoptotic activity. 
Finally, the expression pattern of genes associated with heart disease was not consistent with 
ongoing pathology. Thus, while the decreased heart size is an obvious phenotype, these results 
seem to indicate that hearts in N171-82Q and zQ175 HD mouse models are not failing. These 
observations infer, then, that mHTT expression alone may not be sufficient for pathology. 
Echocardiography data was the first indication of absence of heart failure and mimics 
results obtained on MRI from the R6/2 and HdhQ150 models, showing decreased chamber size 
but normal ejection fraction (83, 86). These metrics alone do not, however, rule out heart failure 
with preserved ejection fraction (HFpEF), a form of heart disease characterized by diastolic 
dysfunction resulting from impaired ventricular relaxability. While cardiac MRI only showed mildly 
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distorted axis in R6/2 mice, the ex vivo pressure analysis supported HFpEF by showing 
decreased passive filling and increased atrial filling, indicating stiff, weak ventricles (86). Thus, 
morphologic metrics are insufficient to properly diagnose HFpEF and require either 
echocardiography with tissue Doppler and/or ex vivo pressure analyses, both of which should be 
employed in the N171-82Q and zQ175 models in future studies However, while my 
echocardiography studies can’t rule out HFpEF, histology and gene expression analysis showed 
a lack of heart pathology, thus disfavoring HFpEF and supporting the more benign phenotype of 
small but functional heart. 
Though heart mass seems to be regulated independent of body mass, metabolic studies 
were performed to determine if a hypermetabolic state could explain changes in heart size. 
Indeed, increased basal metabolic rate can lead to a negative energy balance and thus weight 
loss. Surprisingly, results showed that HD mice had a similar metabolic rate as WT mice during 
the dark cycle but were hypometabolic during the light cycle at later disease stages (Figure 12-
13). HD mice were also more active relative to WT, especially during the light cycle (when mice 
typically sleep) consistent with reports that HD disrupts sleep-wake cycles and circadian 
rhythmicity (105). However, it is intriguing that decreased VO2 and VCO2 were observed, even 
with this increased activity. Furthermore, this data suggests that if activity were controlled for, the 
hypometabolic state observed in the HD animals would be even more severe than what was 
observed. This conclusion is puzzling given the weight loss phenotype in HD mice; usually 
decreased metabolism is associated with increased body weight. Metabolism in HD is more 
nuanced than simply increased or decreased—brain MRI in HD patients revealed striatal 
hypometabolism concomitant with cortical and cerebellar hypermetabolism (106)—but the 
systemic phenotype doesn’t seem to fit with the metabolic data. One of the leading explanations 
for this discrepancy may be the ambient room temperature: for these studies mice housed at 
22°C, whereas the metabolic cages were in a room that, due to facility reasons and inability to 
control individual room temperatures, was only 18°C. Hypothermia is a well-characterized 
phenotype of HD mice linked to impaired brown fat activation (107), and thus being housed in a 
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colder-than-normal environment may have aggravated this phenotype and confounded metabolic 
regulation. Consequently, these results should be interpreted cautiously. 
Heart failure-associated gene expression was generally absent in HD hearts relative to 
WT hearts; when changes were present they either occurred in the opposite direction or at a 
magnitude significantly lower than that associated with disease. However, while expression 
changes may not be physiologically relevant or represent a small subset of cardiomyocytes, in 
many instances they occurred only in early stage N171-82Q animals but resolved at later disease 
stages. This distinction is relevant because one of the large questions with regard to HTT-
targeting therapies is when to begin treatment; in other words, when does the disease start? 
There is increasing evidence to suggest that HD has a developmental component (108), and thus 
understanding the changes that occur in the premanifest stage are vital to understanding the 
whole phenotype. 
The lack of apparent heart pathology does not mean there is no phenotype. Small heart 
size is clearly apparent in the HD mice studied here, which recapitulates HD patients (46) and 
replicates observations from other HD mouse models (37, 84, 86). Unfortunately, the molecular 
characteristics of the HD patient heart have not yet been studied, so it is impossible to know if the 
histological and gene expression changes—or lack thereof—observed in mice are accurate. The 
data I show here suggest that small heart size and mHTT expression may be relatively benign 
under the conditions studied, but work in subsequent chapters will explore mechanisms 
underlying heart mass regulation in HD animals and conditions in which the phenotype is 
detrimental. 
Materials and Methods 
Animals 
All animal protocols were approved by the Animal Care and Use Committee at The 
Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous zQ175 HD murine 
model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained on a 
B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped using primers 
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specific for human HTT, and age-matched WT littermates were used as controls for all 
experiments. All experiments were performed with male mice exclusively. Animals were housed 
in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food and water 
were provided ad libitum. 
Transthoracic Echocardiography 
All echo procedures were performed at the CHOP Small Animal Imaging Facility.  Mice 
were anesthetized with 2.5% isoflurane and positioned on a heated stage with continuous EKG 
measurement. Transthoracic echocardiograms were recorded using an MS-400 30 MHz probe 
connected to a Vevo 2100 or 3100 imager with cardiovascular measurement package. (Fujifilm 
VisualSonics). Parasternal long axis views with Doppler were used to calculate aortic ejection 
time and mitral valve flow dynamics. Parasternal short axis M-mode views at the level of papillary 
muscles were used to calculate posterior wall, septum, and ventricular diameter each at end 
diastole and end systole. Images were acquired and dimensions measured by Christine J. 
Pascua, an experienced operator blinded to mouse genotype. Stroke volume was calculated as 
the difference between left ventricular end diastolic and systolic volumes, and cardiac output 
calculated as the stroke volume multiplied by the heart rate. 
Heart Mass Analysis 
Mice were massed, then anesthetized with a mixture of ketamine/xylazine (IP injection of 
100 mg/kg and 10 mg/kg, respectively) and transcardially perfused with cold saline. Whole hearts 
were excised with atria intact, blot-dried, and massed on an analytical balance. Left tibias were 
removed and measured with electronic calipers to control for variation in total body size. 
Histology 
Excised hearts were bisected transversely at the approximate midpoint, and apical 
portions were post-fixed overnight in 4% paraformaldehyde. Heart tissue was dehydrated and 
embedded in paraffin by the CHOP Pathology Core, and sectioned to 5-7 µm. Sections were 
originally cut on a sledge microtome (Leica SM2010R), but were later cut on a standard rotary 
microtome (Microm HM 355s) because it was determined the retract function—not available on 
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the sledge models—significantly prevents artifacts. Mounted sections were heated at 56-60°C for 
20 minutes to remove excess paraffin, flatten sections, and prevent detachment. Sections were 
allowed to cool to RT and rehydrated before continuing with staining procedures. All sections 
were imaged on a Leica DM6000B light microscope. 
Masson’s Trichrome stain: sections were incubated in 56°C Bouin’s solution (Sigma) for 
10 minutes, followed by staining with Masson’s Trichrome (Sigma) according to standard 
procedure. Briefly, tissues were stained with working Weigert’s iron hematoxylin for 5 
minutes, rinsed in deionized water, and then stained in Biebrich scarlet-acid fuchsin for 5 
minutes. Slides were rinsed in deionized water, fixed in working 
phosphotungstic/phosphomolybdic acid solution for 5 minutes, and then immediately 
stained with aniline blue solution for 5 minutes. Sections were destained in 1% acetic 
acid for 2 minutes, rinsed in deionized water, dehydrated through ethanol, cleared in 
xylene, and mounted.  
Wheat germ agglutinin: sections were washed twice for two minutes in tap water, then 
placed into a solution of 10 µg/ml wheat germ agglutinin and 2 µg/ml Hoechst stain in 
PBS. Slides were stained for 15 minutes at 37°C, then washed twice for two minutes in 
deionized water and mounted with fluorogel. For quantitative analysis, images were taken 
throughout the posterior wall to encompass all transversely-sectioned cells. ImageJ was 
used to overlay a grid on each image to randomly select approximately 50 cells/image 
and cross-sectional area was measured for each selected cell by either manually 
circumscribing the cell exterior or using the threshold function and magic wand tool. At 
least 200 cells were measured per heart.  
Ventricular cardiomyocyte isolation 
12-13 weeks old mice were anesthetized by sodium pentobarbital (50 mg/mL) with 
Heparin (55 units/mL) through i.v. injection (1 mL/1 kg). Hearts were excised, perfused 
retroaortically (Langendorff), and enzymatically digested with a mixture of collagenase (Type 2) 
(Worthington, 250 units/mL), hyaluronidase (Sigma, 0.01%), and protease type XIV (Sigma, 
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0.0025%) in a modified Tyrode’s solution (0.1mM CaCl2, 10 mM BDM). Dissociated 
cardiomyocytes were washed three times in Joklik MEM (Sigma) with 1 % Pen/Strep and 1X ITS 
(Sigma) with increasing Ca2+ (0.25, 0.5, 0.75 mM). Isolated myocytes were cultured with media 
consisting a 50:50 mix of DMEM and F10 media with 1% Pen/Strep and 1X ITS. Primary adult 
cardiomyocyte isolation was performed by Dr. Olha Koval at the University of Iowa. 
TUNEL Stain 
Mice hearts were postfixed overnight in 4% PFA, and 6-μm thick sections were collected. 
TUNEL staining was performed using TACS® 2 TdT DAB Kit (Trevigen). An investigator blinded 
to the mouse genotype and treatments assessed the number of TUNEL-positive cells. Images 
were captured using an Olympus BX60 light microscope and DP70 camera with Olympus DP 
Controller software. 
Metabolic Assessments 
Comprehensive laboratory animal monitoring system (Oxymax) was used to measure 
systemic metabolic rate in HD and WT mice. Animals were singly-housed in a metabolic cage for 
48 hours with continuous monitoring of oxygen input and output, carbon dioxide input and output, 
activity, and food. Gas measurements and calculations of VO2 and VCO2 were made by 
calibrated instruments integrated into the system (both represented as ml gas/kg body 
mass/hour). Cages were fitted with infrared beam grids that measured activity levels, and food 
dispensers were placed on top of scales that measured the mass of food removed. The first 24 
hours of data was considered a habituation period and was discarded. Data was stratified 
between light cycle and dark cycle because of circadian regulation of metabolism. Statistical 
comparisons were calculated between genotypes at the same time point and at the same time of 
day. 
Quantitative PCR 
RNA was isolated using TRIzol (Ambion) according to manufacturer’s protocol. Random-
primed first-strand cDNA synthesis was performed using 2 µg RNA (High Capacity cDNA 
Reverse Transcription Kit; Applied Biosystems) according to manufacturer’s protocol. cDNA was 
24 
 
diluted to 1 ng/µl with DNase/RNase-free water. Quantitative PCR was performed using SYBR 
green PCR master mix (Invitrogen) on a real-time CFX384 PCR detection system (Bio-Rad). 
Primers were designed with Primer3 using strict prediction parameters (no possibility of primer 
dimers, hairpins, or primer pair interaction) or were ordered as predesigned sets (IDT). Manually 
designed primers were validated and optimized multiple concentrations for forward and reverse 
primers in a standard PCR protocol with template cDNA isolated from a random WT heart. PCR 
products were separated by agarose gel electrophoresis, and primers were considered 
acceptable if a single, clear band was detected. If multiple bands were detected, or if the single 
band were faint even at high concentrations, the primer pair was rejected. Melt curve analysis 
was used to further validate primer sets, and primers were rejected if multiple peaks were 
present. Primer sequences are listed in table 1. 
 The 2-ΔΔCt method was used for analysis. Ct values from each gene were normalized to 
endogenous expression of a housekeeping gene (ΔCt), then the average values for samples of 
interest compared to average values of control samples (ΔΔCt). Multiple housekeeping genes 
were assessed over the course of the study and included β-actin, β-tubulin, GAPDH, HPRT, 
RPLP0, Cytochrome C, and TATA-binding protein (TBP). TBP was selected for analyses 
because Ct values were equal between HD and WT samples both at all time points in N171-82Q 
hearts and in zQ175 hearts. 
Statistical Analyses 
All data was analyzed either by Student’s T-test, with p ≤ 0.05 considered significant. 
Statistics were performed in GraphPad Prism version 7. 
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Table 1: List of custom-designed primers for chapter 2 
Gene Name Forward Primer Reverse Primer 
Bax GCAGCTGACATGTTTGCTGATG AGCCCATGATGGTTCTGATCAG 
Bcl2 AGCCTGAGAGCAACCCAATG CGGTAGCGACGAGAGAAGTC 
Fhl1 CTGCCTGAAGTGCTTTGACAAG AAGCAGTTGTCGTGCCAGTAG 
Fhl2 TGGAACCAAGAGCTTCATACCTAAG GGCTGCTCCCGGTAAGTAAC 
Nppa (Anp) TGGGCTTCTTCCTCGTCTTG TCATCTTCTACCGGCATCTTCTC 
Nppb (Bnp) TAGCCAGTCTCCAGAGCAATTC GTGAGGCCTTGGTCCTTCAA 
S100a4 GTGTCTTCCTGTCCTGCATTG CAACACTTCATCTGAGGAGTCTTC 
Tbp TACCGTGAATCTTGGCTGTAAAC GTTGTCCGTGGCTCTCTTATTC 
Vgl4 GAACCGGCCCTCTGTGATTAC 
 
CAGACCCAGGCGCAGAAC 
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Figure 1: N171-82Q hearts have smaller size but normal function on echocardiography. 
Heart function in WT (n = 11) and N171-82Q (n = 14) mice at 16 weeks of age (end-stage 
disease) measured by transthoracic echocardiography, parasternal short axis, M-mode view. 
Results show decreased heart size in HD mice but normal functional. (A) Left ventricular end 
diastolic volume (LVEDV); (B) left ventricular end systolic volume (LVESV); (C) left ventricular 
(LV) mass; (D) heart rate (HR); (E) stroke volume (SV); (F) cardiac output (CO); (G) ejection 
fraction; (H) fractional shortening. Error bars represent standard error of the mean (SEM). 
Students T-test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 2: zQ175 hearts are smaller but function normally on echocardiography. 
Heart function in WT (n = 14) and zQ175 (n = 17) mice at 18 months of age 
(symptomatic) by transthoracic echocardiography, parasternal short axis, M-mode view. Similar to 
N171-82Q mice, results show decreased heart size in HD animals but normal functional. (A) Left 
ventricular end diastolic volume (LVEDV); (B) left ventricular end systolic volume (LVESV); (C) 
left ventricular (LV) mass; (D) heart rate (HR); (E) stroke volume (SV); (F) cardiac output (CO); 
(G) ejection fraction; (H) fractional shortening. Error bars represent standard error of the mean 
(SEM). Students T-test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 3: N171-82Q hearts are grossly smaller than WT littermates. 
(A) Images of a typical N171-82Q heart juxtaposed with a typical WT heart at excision, 
showing clear size discrepancy but no apparent morphological abnormalities. (B) Mass of N171-
82Q and WT mouse hearts measured at 6 weeks (presymptomatic, n ≥ 6), 10 weeks (early-stage 
disease, n ≥ 10), 14 weeks (mid-stage disease, n ≥ 8), and 18 weeks (late-stage disease, n ≥ 8). 
Growth curves show that the mass differences are due to failure of N171-82Q hearts to gain 
mass relative to WT, not atrophy. Error bars represent SEM. Students t-test, ***p ≤ 0.001.  
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Figure 4: Heart size in HD mice is not limited by growth factor availability. 
Assessment of (A) tibia lengths, and (B) heart mass to tibia length ratios in N171-82Q 
mice and WT littermates at 6 weeks (n ≥ 6), 10 weeks (n ≥ 10), 14 weeks (n ≥ 8), and 18 weeks 
(n ≥ 8). Tibia lengths are not different between genotypes at any time point, indicating that limited 
heart growth in HD mice is not due to decreased growth factor levels. Error bars represent SEM. 
Student’s t-test, ***p ≤ 0.001. 
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Figure 5: Heart mass does not change proportional to body mass in N171-82Q mice. 
 Changes in (A) body mass and (B) heart mass to body mass ratio in N171-82Q mice and 
WT littermates. (C) Heart mass and body mass plotted together to show differences in growth 
curves. All graphs include data from N171-82Q and WT mice at 6 weeks (n ≥ 6), 10 weeks (n ≥ 
10), 14 weeks (n ≥ 8), and 18 weeks of age (n ≥ 8). Results show decreased body mass in N171-
82Q mice relative to WT starting before symptom onset and continuing through disease, with 
proportional heart mass at early stages. At later stages, body mass decreases but spares the 
heart. Error bars represent SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 6: Heart size is decreased in symptomatic zQ175 mice. 
(A) Heart mass, (B) heart mass-to-tibia length ratios, and (C) tibia length in 12 month-old 
(symptomatic) heterozygous zQ175 mice (n = 12) and WT littermates (n = 12). Similar to N171-
82Q mice, 12 month-old zQ175 mice have smaller heart mass and heart mass-to-tibia length 
ratios, with no difference in tibia lengths, suggesting that smaller heart mass is not secondary to 
lack of growth factors. Error bars represent SEM. Students t-test, **p ≤ 0.01, ***p ≤ 0.001. 
  
32 
 
 
Figure 7: Heart size in zQ175 mice is proportional to body mass. 
(A) Body mass and (B) heart mass-to-body mass ratio in in heterozygous, 12 month-old 
zQ175 mice (n = 12) and WT littermates (n = 12). At this time point, zQ175 mice weigh less than 
WT littermates, with heart mass proportional to body mass. Error bars represent SEM. Students t-
test, **p ≤ 0.01. 
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Figure 8: Cardiomyocyte cross-sectional area is decreased in symptomatic HD mouse 
hearts. 
(A) Representative wheat germ agglutinin-stained sections from N171-82Q mice at WT 
littermates at 6 and 14 weeks of age, and from zQ175 mice and WT littermates at 12 months of 
age. Scale bars = 20 µm. (B) Calculation of cardiomyocyte cross-sectional area in N171-82Q and 
WT hearts at 6 weeks (n = 4 for each group) and 14 weeks of age (n = 6 for each group). (C) 
Cardiomyocyte cross-sectional area calculated for zQ175 (n = 8) and WT (n = 6) mouse hearts at 
12 months of age. Data show reduced cross-sectional area in HD hearts in N171-82Q hearts at 
14 weeks of age and in zQ175 hearts at 12 months of age, mirroring heart mass observations. 
Mean cross-sectional area for each heart was calculated from > 200 cardiomyocytes. Student’s t-
test, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 9: Isolated N171-82Q cardiomyocytes have decreased surface area. 
Transillumination confocal microscopy image of cardiomyocytes isolated from 14 week-
old N171-82Q and WT littermates. Surface area is decreased in cells from HD mouse hearts (n = 
27 cells) relative to WT littermates (n = 30 cells). N = 3 mice/genotype. Error bars represent SEM. 
Student’s t-test, ***p ≤ 0.001. Samples were imaged and measured by John Lee. 
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Figure 10: N171-82Q and zQ175 mouse hearts are not fibrotic. 
Masson’s trichrome staining in sections from N171-82Q and WT mouse hearts at 6 (n = 
4/group) and 14 (n = 6/group) weeks of age, and from zQ175 and WT mouse hearts at 12 months 
of age. Nuclei stain black, muscle tissue stains red, and collagen (fibrosis) stains bright blue. No 
fibrosis was observed in either HD or WT hearts, in either mouse line, and at any time point. 
Scale bars = 40 µm. 
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Figure 11: N171-82Q mouse heart sections do not show evidence apoptosis. 
 Representative TUNEL staining in 18 week-old N171-82Q mouse heart sections (n = 4) 
and positive control showing complete absence of positive-staining cells in late-stage HD mouse 
heart. Apoptotic nuclei stain black. Scale bars = 50 µm. Sections were stained and imaged by 
John Lee. 
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Figure 12: Longitudinal metabolic analysis of N171-82Q mice. 
Comprehensive laboratory animal monitoring system (CLAMS) cages were used to 
measure metabolic state in N171-82Q animals at 9 weeks (n ≥ 6), 13 weeks (n ≥ 3), and 17 
weeks (n ≥ 6). (A) Oxygen consumption (VO2) is decreased in HD mice at 13 and 17 weeks of 
age during the light cycle only. (B) Carbon dioxide production (VCO2) is decreased in HD mice at 
13 and 17 weeks during the light cycle only. (C) HD mice are more active than WT mice during 
the light cycle at all time points measured, and during the dark cycle at 13 and 17 weeks of age. 
(D) HD mice eat less than WT mice during the light cycle, but eat more during the dark cycle, 
leading to no difference in total daily caloric intake. Error bars represent SEM. Student’s t-test, *p 
≤ 0.05. 
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Figure 13: Metabolic analysis of 12 month-old zQ175 mice. 
Metabolic readouts were measured in 12 month-old zQ175 mice (n = 3) and WT 
littermates (n = 3). (A) VO2 is decreased in HD mice during the light cycle but not the dark cycle 
relative to WT littermates. (B) VCO2 is decreased in HD mice during the light cycle but not the 
dark cycle relative to WT littermates. (C) HD mice are more active than WT littermates during the 
light cycle and have a non-significant increase in activity during the dark cycle. (D) HD mice have 
a non-significant decrease in food intake during the light cycle relative to WT littermates. Error 
bars represent SEM. Student’s t-test, *p ≤ 0.05. 
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Figure 14: Cardiac wall stress-related genes are decreased in HD mice. 
Quantitative PCR analysis of genes typically upregulated with cardiac wall stress in 
N171-82Q mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in 
zQ175 mice at 12 months of age (n ≥ 10): (A) Anp, and (B) Bnp. Both Anp and Bnp expression is 
decreased at 14 and 18 weeks in N171-82Q mouse hearts relative to WT, and Bnp is also 
decreased at 6 weeks. No differences exist between zQ175 and WT mouse hearts. All genes 
were normalized to TATA-binding protein (Tbp) as an internal control and are graphed relative to 
WT. Error bars represent the SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 15: Fetal gene expression is not significantly altered in HD mice. 
Quantitative PCR analysis of two fetal genes that are reactivated during heart failure, (A) 
Fhl1, and (B), Fhl2. Expression was queried in N171-82Q mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 
14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10). Mildly 
increased Fhl1 expression was detected in N171-82Q hearts at 6 weeks, but its magnitude is less 
than that observed in heart failure; additionally, Fhl1 and Fhl2 expression are decreased in N171-
82Q hearts at 14 weeks and otherwise not different, suggesting expression of these genes are 
not altered at a physiologic level and implying that cardiac remodeling is not occurring in HD 
mouse model hearts. All genes were normalized to TATA-binding protein (Tbp) as an internal 
control and are graphed relative to WT. Error bars represent the SEM. Student’s t-test, *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001. 
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Figure 16: Apoptosis genes are elevated only in early-stage N171-82Q mice. 
 Quantitative PCR analysis of genes associated with apoptosis in N171-82Q mouse 
hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12 
months of age (n ≥ 10): (A) the pro-apoptotic factor Bax, and (B) the anti-apoptotic factor Bcl2. 
Early-stage N171-82Q hearts have mildly but significantly elevated Bax, but otherwise no 
expression differences are present between HD and WT mouse hearts. Thus, a low level of 
apoptosis may occur at early-stage disease but resolves in later stages. Error bars represent the 
SEM. Student’s t-test, *p ≤ 0.05, ***p ≤ 0.001.  
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Figure 17: Cardiac pathology-associated genes are only elevated in early-stage N171-82Q 
hearts. 
Quantitative PCR expression of genes associated with heart pathology in N171-82Q 
mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice 
at 12 months of age (n ≥ 10). (A) Vgl4 and (B) S100a4 are generally upregulated with heart 
disease, whereas (C) Serca2a expression generally drops. In HD hearts there is mild but 
significant upregulation of Vgl4 and S100a4 at early N171-82Q stages and in symptomatic zQ175 
mice, but the changes resolve in N171-82Q hearts at later stage disease. Error bars represent 
the SEM. Student’s t-test, *p ≤ 0.05, ***p ≤ 0.001.  
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CHAPTER 3: MTORC1 DYSREGULATION IN HD MOUSE HEARTS 
Introduction 
Diminished heart size observed in HD mouse models was not necessarily associated 
with heart failure, but the heart’s body mass-independent regulation suggested a cell-intrinsic 
mechanism that may have other adverse consequences. One of the key regulators of heart size 
and stress response is mechanistic Target of Rapamycin complex 1 (mTORC1), a serine-
threonine kinase that integrates multiple environmental cues and promotes cellular growth and 
metabolism (109). Conditions favorable to growth promote mTORC1 activity by signaling through 
growth factors and nutrient-sensing mechanisms; conversely, settings in which resources are 
limited, such as hypoxia and starvation, inhibit mTORC1 activity (109). Multiple downstream 
cellular mechanisms are regulated by mTORC1 phosphorylation, including activation of global 
translation (110, 111), cholesterol biosynthesis (112, 113), nucleotide biosynthesis (114, 115), 
mitochondrial and ribosome biogenesis (116, 117), and inhibition of autophagy (118). Thus, 
diminishing mTORC1 activity attenuates cellular growth pathways and activates survival 
mechanisms. 
In the heart, mTORC1 seems to be most critical during the prenatal period, as abolishing 
mTORC1 activity by ablating the activating subunit of mTORC1, Rheb, caused defective 
cardiovascular development (119). Additionally, cardiac-specific Rheb knock-out (KO) mice had 
reduced cardiac mRNA translation, retarded cardiomyocyte growth, and impaired cardiac function 
during the early postnatal period (120). In the adult heart, mTORC1 more expendable but still has 
a vital role in maintaining heart function (121) and responding to stress (122, 123). Given its role 
in promoting growth, mTORC1 dysregulation is an attractive potential mechanism to explain the 
small heart phenotype in HD mice. 
mTORC1 activity has previously been studied in the context of HD, but findings among 
different studies have not always agreed. mHTT aggregates in HD cells are cleared primarily by 
autophagy, and indeed, inducing autophagy with the mTORC1 inhibitor rapamycin limited 
aggregate number and improved neuropathology particularly when administered before symptom 
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onset (124). Interestingly, the N-terminal domain of mTOR—the mTORC1 catalytic subunit—
forms an extended superhelical solenoid due to multiple HEAT motifs, similar to HTT (125, 126). 
mTOR was also found to be sequestered in mHTT aggregates, though how it affects its activity is 
not well understood (124). In R6/2 mouse skeletal muscle, mTORC1 is inappropriately increased 
and may contribute to atrophy in that setting (127). Furthermore, mTORC1 activity is upregulated 
in multiple HD cell models, and restricting its activity improved in vitro pathologic phenotypes 
(128, 129). However, mTORC1 activity is decreased in brains from both HD patients and HD 
rodent models starting at an early time point (130). Furthermore, restoring mTORC1 activity to 
WT levels in HD mouse skeletal muscle and brain alleviated pathology, implying that mTORC1 
activity in HD is both tissue-specific and has a central role in the phenotype. 
Given mTORC1’s importance in heart size and stress adaptation, mTORC1 activity may 
be compromised in the HD heart, which could limit heart growth and potentially cause phenotypic 
changes that predispose the development of cardiomyopathy. Considering the diminished heart 
size in HD mice and mTORC1 observations in HD mouse brains, I hypothesized that mTORC1 
activity would be decreased in HD mouse model hearts. Additionally, given that heart mass 
regulation seems to be independent of body mass, I hypothesized that cardiac mTORC1 
dysregulation would result as a consequence of cell-intrinsic mHTT expression. 
Results 
mTORC1 activity is decreased in HD mouse hearts 
I analyzed mTORC1 activity by assessing phosphorylation of two downstream mTORC1 
targets, ribosomal protein S6 (phosphorylated form abbreviated P-S6) and initiation factor 4E 
binding protein 1 (4EBP1, phosphorylated form abbreviated P-4EBP1). Functionally, mTORC1-
mediated phosphorylation of these proteins enhances activity of S6 and inhibits the inhibitory 
4EBP1, together leading to a global increase in protein translation (109). However, mTORC1’s 
downstream pathways—including translation—are also subjected to other regulators. Thus, for 
the purposes of this work, levels of P-S6 and P-4EBP1 serve only as indicators of mTORC1 
activity. 
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In HD mouse model heart lysates, P-S6 and P-4EBP1 were decreased relative to WT at 
every time point analyzed, starting at the presymptomatic stage (6 weeks old) in N171-82Q mice 
and continuing throughout the life of the animals. (Figure 18A-C). P-S6 and P-4EBP1 were also 
decreased in 12 month-old zQ175 mice relative to age-matched WT littermates (Figure 18A-C), 
thus indicating decreased cardiac mTORC1 in both HD mouse models tested. To further confirm 
mTORC1 inhibition, I used immunohistochemistry (IHC) to identify P-S6 in heart sections from 
N171-82Q mice at 6 and 14 weeks of age, and from zQ175 mice at 12 months of age. 
Interestingly, in age-matched WT mice P-S6 stained positively at what appear to be the 
intercalated discs between adjacent cardiomyocytes (Figure 19). Consistent with WB results, P-
S6 staining in sections from both N171-82Q and zQ175 mice was considerably less dense than 
the WT controls (Figure 19). Thus, decreased cardiac mTORC1 activity can be observed on a 
histologic level. 
mHTT knock-down by RNA interference in HD hearts restores mTORC1 activity 
Multiple environmental signals regulate mTORC1 activity, and though the brain is 
relatively protected from these signals, cardiac mTORC1 is susceptible to changes in nutrients, 
growth factors, or oxygen (131). Thus, the dysregulated cardiac mTORC1 in HD animals may 
result from systemic cues or it may be a cell-intrinsic effect. Furthermore, while mHTT expression 
has been confirmed in the heart (8, 9), the R6/2 mouse did not have any cardiac mHTT 
aggregates (83). However, a considerable body of evidence suggests that aggregates associated 
with neurodegenerative diseases may be relatively inert, or even protective, with toxicity occurring 
as a result of soluble conformers (132, 133). Thus, the question of how mHTT expression affects 
the heart is still unknown. 
In order to determine the necessity of mHTT for mTORC1 dysregulation, I employed a 
novel, cardiotropic adeno-associated virus (AAV) developed in the Davidson lab, termed CT.AAV. 
This vector is a variant of AAV serotype 2 containing a nine amino acid peptide sequence 
inserted into its cap gene that imparts strong specificity for cardiomyocyte transduction (Figure 
20). I used CT.AAV to deliver a HTT-targeting miRNA expression system developed by the 
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Davidson lab (134), termed mi2.1, to knockdown (KD) mHTT in N171-82Q mouse hearts. 
Because mi2.1 is human specific, it does not affect endogenous mouse Htt. For controls I used 
either formulation buffer (FB) or a CT.AAV delivering a scrambled miRNA control sequence 
(miCTRL). I observed 40% mHTT knockdown at the RNA level (Figure 21A) and 35% mHTT 
knockdown at the protein level (Figure 21B-C) in hearts from mice injected with CT.AAV.mi2.1. 
Analysis of mTORC1 activity indicators showed no difference in P-S6 or P-4EBP1 levels between 
hearts of FB- and CT.AAV.miCTRL-injected mice, but showed a significant increase in both 
indicators in hearts from mice injected with CT.AAV.mi2.1 (Figure 22A-C). From these data I 
conclude that cardiac mHTT expression is necessary for mTORC1 dysregulation in HD hearts. 
Modest overexpression of mHTT in WT hearts does not impair mTORC1 activity 
Based on the results from mHTT KD studies, I next hypothesized that mHTT is sufficient 
for mTORC1 dysregulation in the heart. To test this, I utilized CT.AAV to express the pathogenic 
N171-82Q HTT fragment in the hearts of WT mice. For controls I expressed either eGFP or a 
non-expanded N171-12Q HTT fragment. I measured the effects against FB-injected mice. 
Though CT.AAV is remarkably cardiotropic, I further limited expression of the transgene by 
driving expression with a chicken troponin T (cTnT) promoter. I confirmed expression of the 
constructs by qPCR (Figure 23A-B) and found that expression of the N171-12Q and N171-82Q 
fragments were similar. Notably, both were considerably less than the expression levels of the 
mHTT fragment in N171-82Q transgenic mice (approximately 20% of transgene levels). mTORC1 
activity as measured by western blot for P-S6 and P-4EBP1 was not different between groups 
(Figure 24A-C). I conclude that the relatively low levels of transgene expression preclude my 
making any solid conclusions on the sufficiency of mHTT expression for lowering mTORC1 
activity. 
Growth factor signal transduction is not impaired in HD mouse hearts 
The mTORC1 activation pathway integrates multiple cellular signals that can either 
promote or inhibit mTORC1 activity (Figure 25). Cardiac mHTT knockdown suggested that 
mTORC1 dysregulation in HD mouse hearts is a cell-intrinsic effect, but other systemic cues may 
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contribute to the phenotype as well. In order to further confirm the cell-autonomous role of cardiac 
mHTT in decreasing mTORC1 activity and to better understand the mechanism by which it 
occurs, I performed a battery of assays examining the mTORC1 upstream signaling pathway to 
pinpoint at what step dysregulation occurs. 
I started my approach considering extracellular factors that could impact mTORC1 
activity. The mTORC1 activation pathway is stimulated by receptor tyrosine kinases (RTK), many 
of which are growth factor receptors, and the ensuing PI3K/Akt/mTOR signaling cascade (135). I 
thus examined the levels of insulin-like growth factor 1 (IGF-1) in HD mouse serum. Surprisingly, 
IGF-1 was increased in N171-82Q mice at 6 weeks of age, despite the decreased cardiac 
mTORC1 activity, suggesting that increased growth factor may be a systemic compensatory 
response (Figure 26A). IGF-1 levels were not different between N171-82Q and WT mice at 14 
weeks of age, and slightly but significantly decreased in 12 month-old zQ175 mice, which may 
contribute to the mTORC1 dysregulation in these animals (Figure 26A). I next considered serum 
insulin levels, another mTORC1-activating signal (131), and found no difference between HD and 
WT in either 6 week-old N171-82Q or 12 month-old zQ175 mice (Figure 26B). I did find, 
however, that serum insulin was decreased in 14 week-old N171-82Q mice (Figure 26B), but 
none of the mice were fasted prior to serum collection, and serum was taken during the light cycle 
when N171-82Q mice eat significantly less than WT littermates (Figure 12). Thus, changes in 
IGF-1 or insulin levels likely do not explain the significant cardiac mTORC1 dysregulation in HD 
mice. 
I next considered impaired extracellular signal transduction as a possible mechanism 
underlying the mTORC1 abnormalities. To this end, I examined expression levels of the IGF-1 
receptor gene (Igf1r) in HD and WT mouse hearts. Cardiac Igf1r levels were not different from 
WT in 6 week-old N171-82Q mice and in 12 month-old zQ175 mice, but they were mildly but 
significantly increased in N171-82Q mice relative to WT starting at 10 weeks of age and 
continuing throughout disease course (Figure 26C). It is possible that this upregulation occurs as 
a compensatory mechanism, as normally it would be expected to increase mTORC1 signaling. In 
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order to identify potential RTK functional abnormalities, I examined Erk phosphorylation, the end 
target of an RTK signaling cascade separate from the PI3K/Akt/mTOR axis. There were no 
differences in cardiac Erk phosphorylation between HD and WT in any of the N171-82Q time 
points tested or in 12 month-old zQ175 mice (Figure 27A-C). Normal Erk activation implies that 
RTK signaling is not impaired, either by lack of extracellular signals or by intrinsically limited 
function. 
Finally, I measured phosphatase and tensin homologue (Pten) expression, a protein that 
functions as an early inhibitor of PI3K/Akt/mTOR signal transduction (109). In N171-82Q mouse 
hearts, Pten was mildly but significantly increased at 6 weeks relative to WT; however, at 10 
weeks of age, Pten expression was slightly decreased relative to WT, and it was normal at later 
N171-82Q time points and in 12 month-old zQ175 mouse hearts (Figure 28). While statistically 
significant, the early changes in N171-82Q hearts are so slight that they are unlikely to be 
physiologically relevant. Together, these data suggest that RTK signaling is not impaired in HD 
mouse hearts, and therefore it does not underlie cardiac mTORC1 dysregulation. 
Intracellular mTORC1 signaling is affected in early-stage HD mouse hearts 
Because extracellular signals and signaling could not explain dysregulated mTORC1, I 
next considered intracellular possibilities (Figure 25). I assessed activity of 3-phosphoinositide-
dependent protein kinase-1 (PDK1), the downstream target of PI3K, by measuring levels of 
phosphorylated Akt (P-Akt); similarly, I assessed activity of Akt by measuring levels of 
phosphorylated mTOR (P-mTOR). In hearts from 6 week-old N171-82Q mice and 12 month-old 
zQ175 mice, levels of P-Akt and P-mTOR were both decreased relative to WT (Figure 29A-C). At 
later time points in N171-82Q mouse hearts, though, levels of P-Akt and P-mTOR normalized and 
were not different from WT (Figure 29A-C). These results suggest that in presymptomatic and 
early disease stages, mTORC1 dysregulation results from decreased activity of the signaling 
cascade. At later stages, however, a separate inhibitory mechanism takes over. 
Cellular energy deficiency activates numerous mechanisms that preserve resources and 
limit growth, and often include mTORC1 inhibition. Though HD mouse model hearts seem to be 
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protected from the processes underlying body mass loss (Figure 5), a cardiac-specific energy 
deficiency may contribute to cardiac mTORC1 inhibition. I therefore examined two mechanisms 
that inhibit key steps in the PI3K/Akt/mTOR signaling cascade, the adenosine monophosphate-
activated protein kinase (AMPK) and FoxO pathways. When adenosine triphosphate (ATP) levels 
are low—from starvation, inefficient oxidative phosphorylation, high energy demands, etc.—
cellular mechanisms can convert two molecules of adenosine diphosphate (ADP) into a molecule 
of AMP and a molecule of ATP. AMP binds to the AMPK complex, exposing a phosphorylation at 
a site on AMPK subunit α (AMPKα) necessary for its activation (136). As AMPK inhibits the 
PI3K/Akt/mTOR signaling cascade, I measured levels of phosphorylated AMPKα (P-AMPKα) in 
HD and WT mouse hearts but found no differences at any time point in N171-82Q mice or in 12 
month-old zQ175 mice (Figure 30A-B). These results infer that HD mouse hearts are not 
experiencing acute energy imbalance from starvation or other mechanisms, and AMPK does not 
contribute to mTORC1 dysregulation in HD mouse hearts. 
A second cellular mechanism that responds to energy stress is the forkhead box protein 
O (FoxO) transcription factor family, a more chronic pathway that coordinates expression of 
genes that generally oppose the downstream functions of mTORC1 (137). Gene targets of the 
FoxO family include gene products that contribute to muscle atrophy, as well as Bnip3, a known 
inhibitor of Rheb, the activating subunit of mTORC1 (138, 139). Furthermore, recent reports have 
associated HD with increased FoxO3 expression in the brain (140). In HD mouse hearts, FoxO1 
expression was elevated relative to WT in both in N171-82Q hearts starting at 6 weeks and in 
zQ175 mouse hearts at 12 months (Figure 31A). FoxO3 expression was elevated only in N171-
82Q hearts at 14 and 18 weeks (Figure 31B). However, expression of Bnip3 in HD hearts did not 
differ from WT at any time point in N171-82Q mice or in zQ175 hearts (Figure 31C). While 
increased FoxO1 and FoxO3 may indicate chronic energy stress, it is not sufficient to increase 
expression of the effector protein Bnip3 and thus the FoxO pathway does not underlie cardiac 
mTORC1 dysregulation in HD mice. 
Mislocalized Rheb may explain mTORC1 dysregulation in later-stage HD mouse hearts 
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While abnormal signal cascade activation was observed in presymptomatic N171-82Q 
and in 12 month-old zQ175 mouse hearts, none of the pathways analyzed were different from WT 
in later-stage N171-82Q mouse hearts. The PI3K/Akt/mTOR signaling cascade represents a key 
mechanism of mTORC1 regulation, but equally important is mTORC1’s subcellular localization. In 
the presence of amino acids, particularly branched chain amino acids (BCAA), mTORC1 is 
localized to cell endomembranes; this step is critical, as removing amino acids even with 
abundant growth factors fails to activate mTORC1 (141). Subcellular localization of many proteins 
is affected in HD (142-145), so I hypothesized that decreased mTORC1 activity may result from 
improper localization of mTORC1 subunits. 
In order to determine if mislocalization of the mTORC1 complex itself underlies its 
diminished activity, I delivered a BCAA cocktail to N171-82Q mice and WT littermates by daily 
intraperitoneal injection for six weeks (146). Interestingly, there was no difference in P-S6 or P-
4EBP1 levels between any of the groups, though the BCAA-injected groups from both genotypes 
had considerably more variation and seemed to have a slight though statistically insignificant 
increase in P-S6 levels compared to saline-injected groups (Figure 32A-C). These results are not 
very specific, but they do help to rule out insufficient BCAA as a reason for cardiac mTORC1 
dysregulation in HD mice. 
The reason mTORC1 localization is essential for its activity is because Rheb, its 
activating subunit and the end target of the PI3K/Akt/mTOR cascade, is an integral membrane 
protein anchored to cellular endomembranes (147). If Rheb is mislocalized, then mTORC1 will 
remain inactive even in the presence of ample amino acids and growth factors (148, 149). I 
therefore performed a membrane extraction on 16 week-old N171-82Q mouse hearts and found 
that Rheb, the activating subunit of mTORC1, was increased in the cytoplasmic fraction and 
decreased in the membrane fraction relative to age-matched WT mouse hearts (Figure 33A-B). 
Rheb localization did not differ between N171-82Q and WT hearts at 6 weeks of age (Figure 
34A-B) or between zQ175 and WT hearts 12 months of age (Figure 35), consistent with previous 
results showing differences in mTORC1 dysregulation between presymptomatic or early-stage 
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HD mice and late-stage HD mice. Altering Rheb’s ability to properly localize has previously been 
shown to inhibit mTORC1 activity, and thus Rheb mislocalization may underlie the impairment of 
mTORC1 in symptomatic HD mice hearts. 
Discussion 
One of the more common phenotypes that exists in multiple HD mouse models and in HD 
patients is diminished heart size, and understanding the underlying molecular mechanisms could 
help clarify the phenotypic variability between mouse models and identify why HD patients have a 
high risk of cardiac-related mortality. In this chapter, I propose that mHTT expression in 
cardiomyocytes leads to cardiac mTORC1 dysregulation. mTORC1 activity was decreased in HD 
mouse hearts from both N171-82Q and zQ175 lines. Additionally, cardiac mHTT expression is 
necessary for this dysregulation, as miRNA-targeted mHTT KD significantly increased mTORC1 
activity in HD hearts. Efforts to discover the mechanism connecting mHTT expression and 
attenuated mTORC1 activity showed different etiologies between early and later stages in HD 
mice: presymptomatic N171-82Q mice and zQ175 mice both experience decreased 
PI3K/Akt/mTOR signaling cascade activity, whereas later-stage N171-82Q mice have normal 
upstream signaling but mislocalized Rheb. Decreased cardiac mTORC1 activity in HD mice is 
consistent with an absence of heart pathology, given that mTORC1 is not critical for the healthy 
adult heart. However, it could predispose to the heart to cardiomyopathy and mortality under 
stress conditions (122, 123). The consequences of diminished cardiac mTORC1 activity are 
considered in Chapter 4. 
While heterozygous zQ175 mice display clear motor symptoms and decreased body 
mass, their cardiac molecular phenotype tends to correlate best to a time point between 6 week-
old and 10 week-old N171-82Q mice. Considering zQ175 heterozygotes experience symptom 
onset around 8 or 9 months of age, and live past 24 months of age, it is reasonable that they 
resemble a fairly early disease stage. Importantly, these observations extend beyond examination 
of the mTORC1 pathway: in Chapter 2, 12 month-old zQ175 mice were generally most similar to 
6 or 10 week-old N171-82Q mice in qPCR analyses of heart failure genes (Figures 14-17), 
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though differences in those analyses were much more subtle. The molecular similarities between 
young N171-82Q and 12 month-old zQ175 mice are much more apparent when comparing 
mTORC1 pathway dysregulation. 
 Knockdown of mHTT in HD mouse hearts was clearly associated with increased cardiac 
mTORC1 activity, permitting me to conclude that cardiac mHTT expression is necessary for the 
decreased mTORC1 phenotype. Conversely, overexpression of mHTT in WT hearts did not have 
an effect on mTORC1 activity, with P-S6 and P-4EBP1 levels similar across all groups. These 
data hint that cardiac mHTT expression alone may not be sufficient to dysregulate mTORC1—an 
intriguing hypothesis given the large body of work detailing abnormal CNS inputs to the heart—
but limited transgene expression prevents any conclusion. Though the benign and pathogenic 
HTT transgenes were expressed at similar levels, it was only about 20% the expression of the 
N171-82Q transcript in transgenic mice, and therefore likely too low to cause a measurable 
phenotype within the experimental timeframe. If mHTT expression were increased, or if the 
experiment were allowed to proceed longer, it may result in a phenotype similar to that seen in 
N171-82Q, or it may be that other systemic factors truly are required in addition to mHTT 
expression to generate a phenotype. However, these questions cannot be answered with the 
data here. Ideally, future work will confirm the necessity and sufficiency of cardiac mHTT 
expression for mTORC1 dysregulation in HD mouse hearts using either a conditional Cre/LoxP or 
CRISPR system to completely ablate or express mHTT in cardiomyocytes. 
Similar to studies in brain (130), cardiac mTORC1 activity was dysregulated before motor 
symptom onset, suggesting that molecular pathogenesis associated with mHTT expression 
begins early and contributes to the notable, limited heart growth. Interestingly, the cause of 
mTORC1 dysregulation results from distinct etiologies based on disease stage. Presymptomatic 
and early-stage mTORC1 dysregulation is associated with decreased PI3K/Akt/mTOR activation, 
whereas upstream signaling activity is normal in later-stage HD mice. RTK function was normal in 
6 week-old N171-82Q and 12 month-old zQ175 hearts as evidenced by normal P-Erk levels, but 
decreased P-Akt suggests signaling is likely impaired at the level between the RTK and PDK1. 
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PDK1 becomes active when it localizes to the cell membrane at phosphoinositides (131), an 
interesting similarity when considering that subcellular localization abnormalities may also explain 
later-stage mTORC1 dysregulation. Further work deciphering this mechanism should therefore 
examine levels of various phosphoinositides in the cell membrane, and determine if PDK1 
localization is impaired in early-stage HD mouse hearts. 
The mTORC1 dysregulation in mid- to late-stage N171-82Q mouse hearts, even when 
upstream signals are normal, is likely due to Rheb mislocalization. Rheb is post-translationally 
modified with a farnesyl group that targets it to the cellular endomembranes in the ER, Golgi, 
mitochondria, and late endosomes/lysosomes (141, 147). Inhibiting this process induces Rheb 
mislocalization and impairs mTORC1 activity (148, 149). Farnesyl is a metabolic precursor 
product in the cholesterol biosynthesis pathway, a process impaired in HD (150, 151), and 
lysosomal cholesterol stores are also essential for proper mTORC1 localization and activation 
(152). While it is still unknown if Rheb in HD hearts mislocalizes due to lack of farnesylation or 
through another mechanism, it is possible that aberrant cholesterol metabolism in HD may 
contribute to the decreased mTORC1 activity observed in both the heart and the brain. 
The failure of BCAA injections to increase mTORC1 activity is a non-specific result, but it 
supports Rheb mislocalization as the reason for decreased mTORC1 activity in later-stage HD 
animal hearts: if Rheb is not present at the cellular endomembranes, BCAA treatment would be 
expected to result in membrane-associated but inactive mTORC1. However, other factors may 
also contribute to the observed lack of effect. For one, the BCAA cocktail may not have been 
concentrated enough to induce an effect in adult mice. It may also be the case that both HD and 
WT mice are eating enough that supplementing BCAA has little effect. Whatever the case, Rheb 
mislocalization is a promising mechanism to explain mTORC1 dysregulation in late-stage HD 
hearts, and, potentially, the brain. Future work should thus focus on confirming the phenotype in 
later-stage zQ175 mice (around 2 years old), applying in vivo cholesterol precursor labeling to 
determine whether it results from impaired farnesylation, and examining if Rheb is similarly 
mislocalized in HD brain samples.  
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Materials and Methods 
Animals 
All animal protocols were approved by the Animal Care and Use Committee at The 
Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous zQ175 HD murine 
model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained on a 
B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped using primers 
specific for human HTT, and age-matched WT littermates were used as controls for all 
experiments. All experiments were performed with male mice exclusively. Animals were housed 
in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food and water 
were provided ad libitum. 
Western Blots 
Hearts were homogenized by beat mill (Qiagen) for 5 minutes at 50 Hz with a 5 mm 
stainless steel bead in 250 ml TBS disruption buffer containing 50 mM Tris (pH 8.0), 150 mM 
NaCl, Complete protease inhibitors (Roche), and Phos-STOP phosphatase inhibitors (Roche). 
Following disruption, 750 ml protein extraction buffer was added to samples containing 50 mM 
Tris (pH 8.0), 150 mM NaCl, 1.333% Triton-X, 0.1333% SDS, 0.667% sodium deoxycholate, 
complete protease inhibitors, and Phos-STOP phosphatase inhibitors. (Combination of disruption 
and extraction buffers in a 250 µl:750 µl ratio yields 1X RIPA buffer containing 50 mM Tris (pH 
8.0), 150 mM NaCl, 1% Triton-X, 0.1% SDS, 0.5% sodium deoxycholate, and 
protease/phosphatase inhibitors.) Samples were allowed to incubate for 1 hour at 4°C with 
agitation before clarifying by centrifuging at 16,000 x g for 15 minutes. Total protein concentration 
was determined by BCA (Pierce). 30 µg of protein was reduced and separated by SDS-PAGE on 
12% bis-tris polyacrylamide gels in MOPS buffer (Bio-Rad), then transferred to 0.2 µm PVDF 
(Bio-Rad). Antibodies used are described in Table 2. Blots were developed using ECL Plus 
Western Blotting Detection System (GE Healthcare) and imaged digitally on a ChemiDoc MP 
imaging system (Bio-Rad). Blots were stripped no more than two times using Restore Stripping 
Buffer (Thermo) for 9 minutes at 37°C. Densitometry was performed using NIH ImageJ software. 
Densities of bands detected by phospho-antibodies were normalized to densities of bands 
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detected by phospho-independent antibodies in same lane. Phospho-independent antibody 
densities were normalized to αTubulin or Na/K-ATPase band in same lane. 
Immunohistochemistry 
Excised hearts were bisected transversely and the apical sections post-fixed in 4% PFA 
for at least 24 hours. Samples were dehydrated and processed by the CHOP Pathology Core. 5-7 
µm sections were cut from paraffin blocks on a rotary microtome (Microm), mounted, then heated 
at 55°-60° to remove excess paraffin and cement sections. Sections were then rehydrated 
through xylene and ethanol, followed by heat-induced epitope retrieval for 3 minutes using a 
pressure cooker and sodium citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6). Slides 
were washed in TBS with 0.025% Triton-X, termed here TBS-TX, and then blocked in 10% 
normal serum with 1% BSA in TBS at RT for 2 hours. Primary antibody P-S6 (Cell Signaling, 
4858, 1:200) was diluted in 1% BSA in TBS-T and incubated on tissue samples overnight at 4°C. 
Sections were washed in TBS-TX and blocked in 0.3% H2O2 the next day. For detection, sections 
were incubated with a biotin-conjugated secondary antibody for 1 hour at RT, followed by 
incubation in ABC solution for 30 min at RT to amplify signal. Sections were developed using 
DAB and H2O2 until color was visible, about 90 seconds. 
After IHC development, slides were counterstained in Harris hematoxylin for 2 minutes. 
Stained sections were rinsed in tap water, destained by two dips in a solution of 70% ethanol and 
0.25% HCl, then allowed to blue by rinsing in running tap water for 2 minutes. Sections were then 
dehydrated through ethanol, cleared in xylene, and mounted with DPX. 
In situ GFP fluorescence microscopy 
Tissues from saline-perfused mice were excised and post-fixed in 4% PFA overnight. 
They were cryoprotected in a solution of 30% sucrose, 0.1 M Tris HCl (pH 7.0), 0.05% NaN3 until 
tissues sank, then moved to liquid OCT. For embedding, tissue molds were placed in a 2-
methylbutane bath so that the 2-methylbutane was over the level of the OCT within the mold but 
not over the top of the mold itself. The system was then placed in liquid nitrogen until the OCT 
solidified. 10 µm tissue sections were cut on a cryostat and sections were allowed to melt onto a 
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SuperFrost Plus slide (Fisher) at RT. Slides were briefly washed 2X in PBS to remove excess 
OCT, mounted with Fluorogel, and imaged on a Leica DM6000B light microscope. 
Viral preparation and gene transduction 
Cardiotropic AAV (termed CT.AAV) was developed by inserting a novel nine-residue 
peptide sequence identified by Yonghong Chen through phage panning into the cap gene of 
AAV2. Genes of interest were cloned into a standard AAV2 expression cassette. MicroRNA 
systems (mi2.1, miCTRL) were previously developed by the lab (134) and were driven by a U6 
promoter. mHTT overexpression systems (eGFP, N171-12Q, and N171-82Q) were made by 
cloning the gene of interest—available on plasmids previously developed by the lab—
downstream of the chicken troponin T (cTnT) promoter. The cTnT promoter has been shown to 
be an effective means of cardiac gene overexpression using AAV transduction (153, 154) and 
was ordered as a custom G-block with unique 5’ and 3’ restriction sites from IDT. All AAVs were 
produced by the Research Vector Core at The Children’s Hospital of Philadelphia. Titers 
(measured in viral genomes/ml) were determined by qPCR. 
For vector delivery, mice were injected with 7.5e10 viral genomes (vg)/g body mass via 
jugular vein injection (JVI) following a validated protocol (155). JVI was selected over tail vein 
injection because of the proximity to the target tissue (heart), and because the relatively large 
size helps minimize loss of valuable vector to technical errors. Briefly, mice were anesthetized 
with isoflurane and placed in the supine position. The skin directly over the right clavicle was 
shaved and cleaned, and a small, superficial incision was made at the approximate midclavicular 
line. The superior insertion point of the right pectoralis muscle was identified and the internal 
jugular vein isolated. The injection was made with an insulin syringe by advancing the needle 
through the pectoralis muscle into the jugular vein. The pectoralis muscle served to both stabilize 
the needle and provide pressure on the vein once the needle was removed. The wound was 
closed by either continuous stitching or wound clips, with wound clips removed 7-10 days after 
surgery. 
Quantitative PCR 
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For in-depth explanation of qPCR protocol, see Chapter 2: Materials and Methods. 
Briefly, RNA was extracted from snap-frozen mouse hearts using Trizol (Ambion). cDNA libraries 
were constructed from 2 µg RNA template using with random hexamer primers and a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green qPCR was 
performed using either custom-designed primer sets, or pre-designed and validated primer sets 
purchased from IDT. Genes that utilized pre-designed primers sets in this chapter include: HTT, 
FoxO1, Bnip3, and Igf1r. For custom-designed primer sets used in this chapter, see Table 3. 
Data was analyzed using either the 2-ΔΔCt method, or by creating a standard curve from known 
concentrations of plasmid DNA each containing a single copy of the gene of interest. 
BCAA Injections 
N171-82Q and WT mice were daily 2 ml injections of a branched chain amino acid 
cocktail containing 6 mg/ml L-isoleucine, 12 mg/ml L-leucine, 7.2 mg/ml L-valine, and 6.04 mg/ml 
L-arginine. Injections were started at 10 weeks of age and continued until 16 weeks of age. At 
experiment endpoint, hearts were excised and snap frozen for WB analysis. 
Membrane Extraction 
Membrane fractions were extracted from snap-frozen heart tissue using a MEM-Per Plus 
kit (Thermo) according to manufacturer’s protocol. Preliminary extraction protocols employing 
Triton-X114 used a bead mill for homogenization and found that all proteins separated with the 
cytoplasmic fraction, thus demonstrating the importance of a more sensitive homogenization 
protocol. For experiments here, tissue was homogenized in the appropriate buffer using a 
Dounce homogenizer, 5 strokes with pestle A (coarse) and 3 strokes with pestle B (fine).  
Statistical Analyses 
All data was analyzed either by Student’s T-test or one-way ANOVA with Tukey’s post-
hoc analysis, with p ≤ 0.05 considered significant for all tests. Statistics were performed in 
GraphPad Prism version 7. 
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Table 2: Antibodies used for Chapter 3 
Company  Antigen Product ID WB Dilution 
Cell Signaling P-S6 (ser235/236) 4858 1:1000 
 S6 2217 1:1000 
 P-4EBP1 (ser65) 9451 1:500 
 4EBP1 9644 1:1000 
 P-Akt (ser473) 4060 1:500 
 Akt  4691 1:1000 
 P-mTOR (ser2448) 5536 1:500 
 mTOR  2983 1:1000 
 P-AMPKα (thr172) 2535 1:1000 
 P-p44/42 MAPK 
(thr202/tyr204) 
4370 1:1000 
 p44/42 MAPK 4695 1:1000 
 Rheb 13879 1:1000 
AbCam Na/K-ATPase  ab76020 1:100,000 
 HTT ab109115 1:5000 
Santa Cruz AMPKα sc-25792 1:1000 
Sigma αTubulin T5168 1:2000 
GE Healthcare Anti-mouse HRP NA931 1:20,000 
 Anti-rabbit HRP NA934 1:15,000 
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Table 3: Custom-designed primers for Chapter 3 
Gene Name Forward Primer Reverse Primer 
FoxO3 GGCAAAGCAGACCCTCAAAC TGGGAGTCTCAAAGGTGTCAAG 
GFP AAGGGCATCGACTTCAAGG TGCTTGTCGGCCATGATATAG 
Tbp TACCGTGAATCTTGGCTGTAAAC GTTGTCCGTGGCTCTCTTATTC 
  
60 
 
 
Figure 18: mTORC1 activity is decreased in HD mouse hearts. 
(A) Representative western blot analysis for P-S6 and P-4EBP1 in hearts of N171-82Q 
mice and WT littermates at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in 
zQ175 mice and WT littermates at 12 months of age (n ≥ 10). Total (phospho-independent) S6 
and 4EBP1 serve as references. Blots were quantitated by densitometry analysis to determine 
(B) P-S6 levels and (C) P-4EBP1 levels in HD mouse hearts relative to WT. Phosphoprotein band 
densities were normalized to total protein band densities from the same lane. Data shows 
decreased P-S6 and P-4EBP1 in HD hearts in both genotypes and at all time points. Error bars 
represent SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 19: P-S6 immunostaining shows decreased mTORC1 activity in HD mouse hearts. 
Immunostaining of heart sections from N171-82Q and WT mice at 6 (n ≥ 5) and 14 weeks 
of age (n ≥ 10), and from zQ175 and WT mice at 12 months of age (n ≥ 10). P-S6 in heart tissue 
seems to stain positive at intercalated discs between adjacent cardiomyocytes. In HD mouse 
hearts, P-S6 stains less dense than in WT hearts, confirming western blot data and suggesting 
decreased mTORC1 activity. Scale bars = 20 µm. 
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Figure 20: CT.AAV preferentially transduces cardiomyocytes. 
Biodistribution analysis of systemically-injected CT.AAV delivering a GFP transgene (n = 
4). Saline-injected animals were used as controls (n = 4), and images here represent in situ GFP 
fluorescence. Sections displayed were taken from heart, liver, and skeletal muscle. AAV typically 
transduces liver at much higher magnitude than the heart, but here ventricle and atria are clearly 
show much more fluorescence than either liver or skeletal muscle. Liver does have a small 
amount of expression relative to saline controls. Skeletal muscle exhibits considerable 
autofluorescence, and there is no distinguishable difference between saline and CT.AAV-injected 
samples. 
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Figure 21: CT.AAV.mi2.1 injection knocks down mHTT in N171-82Q mouse hearts. 
Confirmation of mHTT KD in N171-82Q mouse hearts from animals injected with either 
formulation buffer (FB, n = 8), CT.AAV.miCTRL (n = 8), or CT.AAV.mi2.1 (n = 7). (A) Quantitative 
PCR to determine expression of mHTT mRNA in N171-82Q KD mouse hearts and controls. 
Analysis shows a 40% knock-down in mice from CT.AAV.mi2.1-injected mice relative to FB-
injected controls. Tbp was used as an internal control for each sample. (B) Representative WB for 
HTT protein in N171-82Q KD mouse hearts and controls. Bands displayed represent transgenic 
N171-82Q fragment, which runs at approximately 44 kD. (C) Densitometry analysis of HTT WB to 
confirm mHTT at the protein level. Data were normalized to αTubulin band densities from the 
same lane and graphed relative to FB-injected controls. Results demonstrate a 35% KD of the 
mHTT transgenic fragment in CT.AAV.mi2.1-injected HD mice relative to FB-injected controls. 
Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05, **p ≤ 
0.01. 
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Figure 22: mHTT knock down in N171-82Q mouse hearts restores mTORC1 activity. 
Analysis of mTORC1 activity in N171-82Q mouse hearts injected with either formulation 
buffer (FB, n = 8), CT.AAV.miCTRL (n = 8), or CT.AAV.mi2.1 (n = 7). (A) Representative WB for 
P-S6 and P-4EBP1 in N171-82Q mouse hearts with mHTT KD (mi2.1) or controls. Densitometry 
analysis was performed to quantitate (B) P-S6 levels and (C) P-4EBP1 levels. Phosphoprotein 
band densities were normalized to total protein band densities in the same lane. Data were 
graphed relative to FB and show significantly increased mTORC1 activity in hearts from N171-
82Q mice injected with CT.AAV.mi2.1 relative to controls, suggesting mHTT expression is 
necessary for mTORC1 dysregulation. Error bars represent SEM. One way ANOVA with Tukey’s 
post-hoc analysis, *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Figure 23: Confirmation of transduction in WT mice overexpressing mHTT. 
Quantitative PCR to confirm gene transduction in hearts of WT mice injected with 
formulation buffer (FB, n = 8), CT.AAV.eGFP (n = 8), CT.AAV.N171-12Q (n = 9), or 
CT.AAV.N171-82Q (n = 8). Genes analyzed were (A) eGFP and (B) human HTT. Standard 
curves were generated for each gene and data therefore represent copy numbers/ng RNA. 
Primers for human HTT do not differentiate between 12Q and 82Q variants, but do not amplify 
endogenous mouse HTT. While successful HTT expression is demonstrated, the levels are only 
20% of that in N171-82Q hearts (data not shown). 
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Figure 24: mHTT overexpression in WT hearts does not impair mTORC1 activity. 
(A) Representative WB of mTORC1 activity indicators P-S6 and P-4EBP1 in WT hearts 
injected with either FB (n = 8), CT.AAV.GFP (n = 8), CT.AAV.N171-12Q (n = 9), or 
CT.AAV.N171-82Q (n = 8). Bands shown are from non-adjacent lanes on the same blot. 
Densitometry analysis was used to quantitate levels of (B) P-S6 and (C) P-4EBP1 normalized to 
phospho-independent band densities from the same lane. No differences in mTORC1 activity 
were observed between transduced gene, suggesting that mHTT expression may not be 
sufficient for mTORC1 dysregulation, but these results may also result from relatively low levels 
of mHTT expression. Error bars represent SEM. 
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Figure 25: mTORC1 activation cascade. 
Simplified schematic of mTORC1 activation pathway from extracellular signals to 
mTORC1 phosphorylation of S6 and 4EBP1. Arrows represent activation steps, blunted lines 
represent inhibition steps. Notably not pictured are subcellular localization requirements. 
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Figure 26: Extracellular signals do not contribute to mTORC1 dysregulation in HD mouse 
hearts. 
(A) ELISA analysis of serum IGF-1 from N171-82Q mice and WT littermates at 6 (n ≥ 5) 
and 14 weeks of age (n ≥ 7) and from zQ175 mice at 6 (n ≥ 5) and 12 months of age (n ≥ 12). 
Data are graphed relative to WT for each time point. Surprisingly, IGF-1 was increased in 6 week-
old N171-82Q mice despite decreased mTORC1 activity. (B) ELISA measurement of serum 
insulin from N171-82Q and zQ175 mice at similar time points as panel (A). Note that while serum 
insulin is decreased in 14 week-old N171-82Q mice, serum was collected during the day, at an 
age where daytime feeding is significantly decreased (Figure 12). (C) Quantitative PCR analysis 
of IGF-1 receptor gene expression (Igf1r) in HD mouse hearts relative to age-matched WT 
littermates at  6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age for N171-82Q mice, 
and 12 months of age (n ≥ 10) for zQ175 mice. Tbp expression was used as an internal control. 
Data are graphed relative to WT for each time point. Interestingly, Igf1r expression increases in 
N17-82Q mice with age, suggesting a possible compensatory role. Error bars represent SEM. 
Student’s T-test, *p ≤ 0.05, **p ≤ 0.01. 
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Figure 27: Erk activation is not impaired in HD mice. 
(A) Representative western blot analysis of phospho-Erk1 and phospho-Erk2 in N171-
82Q and WT mouse hearts at 6 weeks (n ≥ 6), 10 weeks ( n ≥ 10), 14 weeks (n ≥ 8), and 18 
weeks (n ≥ 8) of age, and in zQ175 and WT mouse hearts at 12 months (n ≥ 6) of age. 
Densitometry quantitation of (B) P-Erk1 and (C) P-Erk2 levels showed no difference in 
phosphorylated protein levels between WT and HD in either line or at any time point, suggesting 
no impairment of IGF-1 signaling. Band densities of phosphoproteins were normalized to 
phospho-independent band densities from the same lane. Data are plotted relative to WT. Error 
bars represent SEM. Student’s T-test (no significant differences). 
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Figure 28: Expression of Pten does not explain mTORC1 dysregulation in HD mouse 
hearts. 
Quantitative PCR to determine Pten expression in N171-82Q at WT mice 6 (n ≥ 6), 10 (n 
≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 and WT mice at 12 months of age (n 
≥ 10). Expression of Tbp was used as an internal control and data were graphed relative to WT 
levels. Pten expression was mildly but significantly increased at 6 weeks in N171-82Q mice, 
decreased at 10 weeks, and normal at later time points and in zQ175 mice. Thus, it is highly 
unlikely that it is affecting mTORC1 activity. Error bars represent SEM. Student’s T-test, *p ≤ 
0.05. 
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Figure 29: Diminished upstream pathway activation may explain mTORC1 dysregulation in 
early-stage HD mice. 
(A) Representative WB and quantitation to assess levels of (B) phospho-Akt (P-Akt) and 
(C) phospho-mTOR (p-mTOR) in N171-82Q mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 
8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10). Age-matched WT littermates 
were used as controls. Protein levels were quantitated by densitometry analysis, normalizing 
band densities of phosphoproteins to band densities of the same phospho-independent protein. 
Decreased levels of P-Akt and P-mTOR in 6 week-old N171-82Q and 12 month-old zQ175 mice 
relative to WT suggests decreased axis activation, explaining the dysregulated mTORC1 at these 
time points. However, in post-symptomatic N171-82Q mice the axis activation normalizes but 
mTORC1 activity is still dysregulated, suggesting a distinct etiology in later disease stages. Error 
bars represent SEM. Students T-test, *p ≤ 0.05, **p ≤ 0.01. 
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Figure 30: AMPK is not activated in HD mouse hearts. 
(A) Representative WB and (B) densitometry quantitation for activated (phosphorylated) 
AMPK in N171-82Q mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in 
zQ175 mice at 12 months of age (n ≥ 10). Age-matched WT littermates were used as controls. 
Phosphoprotein band densities were normalized to phospho-independent protein band densities 
and graphed relative to WT. No differences were observed, suggesting that AMPK is not 
activated in N171-82Q or zQ175 hearts at the time points tested and therefore does not explain 
mTORC1 dysregulation. Error bars represent SEM. Student’s T-test. 
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Figure 31: Expression of FoxO1 and FoxO3 are increased in HD but may not contribute to 
mTORC1 dysregulation. 
Quantitative PCR analyses to determine expression levels of FoxO-family transcription 
factors and downstream product Bnip3, an mTORC1 inhibitor, in N171-82Q hearts at 6 (n ≥ 6), 10 
(n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10). 
Levels of (A) FoxO1 are increased at all time points in N171-82Q mice and in zQ175 mice relative 
to WT. Additionally, levels of (B) FoxO3 are increased at 14 and 18 weeks in N171-82Q mice. 
However, while significant, the increases are relatively mild, and expression of (C) Bnip3 is not 
different from WT at any time point in either mouse line. Thus, while the FoxO transcription 
factors may be mildly upregulated in HD mouse hearts, it is unlikely that they are having an effect 
on mTORC1. All genes used Tbp as an internal control and are graphed relative to WT. Error 
bars represent SEM. Student’s T-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 32: BCAA injection does not restore mTORC1 activity in N171-82Q mice. 
(A) Representative western blot and densitometry analysis of (B) P-S6 and (C) P-4EBP1 
levels in hearts from N171-82Q and WT mice injected daily with branched chain amino acid 
(BCAA) cocktail starting at 10 weeks of age and continuing until 16 weeks of age. For each 
group, n ≥ 6. Phosphoprotein band densities were normalized to phospho-independent band 
densities for the same protein in the same lane. Results show that BCAA injections did not 
significantly increase mTORC1 activity mouse hearts of either genotype. Error bars represent 
SEM. One-way ANOVA with Tukey’s post-hoc analysis. 
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Figure 33: Rheb is mislocalized in late-stage N171-82Q mouse hearts. 
Membrane extraction of 16 week-old (late-stage disease) N171-82Q and WT mouse 
hearts (n = 6/genotype), followed by WB for Rheb, shows preferential Rheb localization in the 
cytoplasmic fraction rather than the membrane fraction. (A) Representative WB and (B) 
densitometry quantitation normalizing to Na/K-ATPase for membrane fraction and αTubulin for 
cytoplasmic fraction. Error bars represent SEM. Student’s T-test, ***p ≤ 0.001. 
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Figure 34: Rheb localization is not altered in 6 week-old N171-82Q mouse hearts. 
(A) Representative WB for Rheb and (B) densitometry quantitation of membrane and 
cytoplasmic fractions from 6 week-old N171-82Q and WT hearts. Na/K-ATPase was used as a 
control for membrane factions and αTubulin was used as a control for cytoplasmic fractions. 
While total cytoplasmic Rheb was moderately but significantly decreased in HD cytoplasmic 
fractions relative to WT, there was no difference in membrane-associating Rheb between HD and 
WT. Thus, it is unlikely that Rheb mislocalization contributes to mTORC1 dysregulation in 
presymptomatic N171-82Q hearts. Error bars represent SEM. Student’s T-test, *p ≤ 0.05. 
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Figure 35: Rheb localization is not affected in 12 month-old zQ175 hearts. 
Representative WB for Rheb in cytoplasmic and membrane fractions from 12 month-old 
zQ175 and WT hearts (n = 6/genotype). Bands were not quantitated due to absence of Rheb 
signal in membrane fractions from both genotypes. Na/K-ATPase and αTubulin were used as 
loading controls for membrane and cytoplasmic fractions, respectively. The absence of 
membrane-localized Rheb in either WT or HD suggests Rheb mislocalization is likely not 
contributing to mTORC1 dysregulation in these hearts. 
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CHAPTER 4: FUNCTIONAL CONSEQUENCES OF CARDIAC MTORC1 
DYSREGULATION HD MICE 
Introduction 
Decreased mTORC1 activity in HD mouse hearts can lead to multiple downstream 
consequences. Cardiac mTORC1 activity is essential for development (119), but it seems to be 
less critical in healthy adult hearts. For instance, the mTORC1-specific inhibitor everolimus is 
commonly used for its immunosuppressive properties in heart transplant patients and has 
excellent outcomes (156), demonstrating that mTORC1 suppression is well tolerated even in 
some of the most fragile hearts. That is not to say, however, that mTORC1 has no function in 
adult hearts: cardiac-specific mTor knockout in adult mice quickly leads to dilated cardiomyopathy 
and death (121). Partially suppressing its activity, though, seems to be well-tolerated in healthy 
hearts. Where mTORC1 activity becomes more obligatory is in mediating the cardiac 
hypertrophic response to stress.  
Cardiac stress occurs when the heart must increase its work to supply the body’s oxygen 
needs. Many different physiologic and pathophysiologic mechanisms can induce cardiac stress, 
including endurance and strength training (157), ischemic heart injury, systemic hypertension, 
valve abnormalities, arteriovenous fistulae, etc. (158). Typically, the heart responds by 
hypertrophy, an adaptive mechanism that decreases the amount of work each individual 
sarcomere must exert while maintaining a sufficient cardiac output (159). Since cardiomyocytes 
are non-dividing cells, hypertrophy occurs by increasing sarcomere size and structure within the 
existing cardiomyocyte; pressure overload causes addition of new sarcomeres in parallel and 
leads to thickened ventricles, whereas volume overload stimulates addition of new sarcomeres in 
series and leads to ventricular dilatation (160). Though heart hypertrophy is initially adaptive, left 
unchecked it becomes pathologic. Eventually ventricular efficiency and compliance decrease, 
coronary blood flow can become impinged by the thickened myocardium, and heart failure 
ensues (82). These maladaptive changes are common end stages of many forms of heart 
disease, so heart hypertrophy studies generally focus on how to delay or stop it. However, in its 
adaptive capacity, hypertrophy provides a role essential to survival. 
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The adaptive or physiologic phase of heart hypertrophy is mediated by mTORC1. 
Comparison of physiologic and pathologic hypertrophy in mice found cardiac mTORC1 activity 
was increased in exercised mice, but decreased in end-stage pressure-overloaded animals (161). 
These observations imply that, with a chronic stressor, the initial adaptive changes are mediated 
by mTORC1, but later maladaptive or pathologic hypertrophy occurs via an mTORC1-
independent mechanism. Accordingly, cardiac-specific mTor knockout mice rapidly developed 
dilated cardiomyopathy with increased apoptosis, fibrosis, and complete lack of hypertrophy in 
response to stress. (121). Conversely, overexpression of mTOR attenuated pressure overload-
induced fibrosis and reduced inflammatory cytokine responses (162). While these phenotypes 
demonstrate the importance of mTOR function in the heart, they necessarily affect mTORC2 
activity, a second mTOR-based complex that promotes cell survival and polarity. A more specific 
mTORC1 ablation was accomplished with cardiac-specific raptor deletion (a defining mTORC1 
subunit), which caused maladaptive responses to pressure overload resulting in dilated 
cardiomyopathy and heart failure (123). Together, these results suggest that the adaptive stress 
response is simply bypassed in the absence of mTORC1, with stress inducing immediate onset of 
pathologic heart hypertrophy and increased mortality.  
While cardiac mTORC1 suppression by small-molecule inhibitors is well-tolerated in the 
absence of heart disease, stressed hearts may be much more sensitive to changes in mTORC1 
levels. Rapamycin, a small molecule mTORC1 inhibitor, prevented cardiac compensation and led 
to increased mortality in volume and pressure overload mouse models (122, 163). Thus, stressed 
hearts have a marked reliance on mTORC1 activity for the physiologic adaptation phase. It is 
thus likely that the mTORC1 dysregulation I observed in HD mouse models underlies the 
previously described inability to hypertrophy (87) and the increased fibrosis (85) in response to 
stress. To test this hypothesis, I first validated the stress response phenotype in HD mice, then 
restored mTORC1 activity by gene therapy techniques to observe how it changed the phenotype. 
Results 
HD mouse hearts do not adapt to cardiac stress 
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In order to induce stress in HD mouse hearts I used continuous isoprenaline (ISO) 
infusion, a non-specific β-adrenergic agonist that binds β-adrenergic receptors with more affinity 
than epinephrine or norepinephrine. ISO treatment is frequently used as a cardiac stress model in 
rodents and mimics adrenergic conditions associated with pressure overload (164). Because 
previous cardiac stress studies in HD animals utilized the R6/2 and BACHD models, I first 
confirmed and further characterized the phenotypes in N171-82Q mice. The most apparent 
response after starting ISO infusions was significantly increased mortality. ISO-treated N171-82Q 
mice at 12 weeks of age experienced 50% mortality over the course of the 14 day study, 
compared to 15% among saline-treated HD mice and 0% among both of the WT groups (Figure 
36). I repeated the experiment in 18 month-old zQ175 mice, expecting to see a lower rate of 
mortality than with the N171-82Q line because of the generally more subtle and slower-
progressing phenotypes. To the contrary, aged zQ175 mice experienced a rapid 83% mortality, 
compared to 25% among the stressed WT mice and 0% in both of the saline treated groups 
(Figure 37). This augmented ISO-related mortality in both genotypes relative to saline-treated 
controls suggests that increased age contributes to pathogenesis, and combined with mHTT 
expression produces robust results. Interestingly, mortality in both studies started almost 
immediately but soon plateaued, with a subset of the stressed HD animals (50% in N171-82Q 
mice and 17% in zQ175) surviving the entire 14 days (Figures 36-37). Thus, the surviving HD 
mice may have been able to achieve some level of adaptation. Nevertheless, the increased 
mortality in both genotypes suggest that, in general, HD mice have limited compensation to 
cardiac stress. 
I explored the in vivo stress response in HD mice using transthoracic echocardiography. I 
obtained imaging data in HD and WT mice at baseline, prior to ISO (or treatment control) delivery, 
and again 5 and 12 days later, and assessed the temporal change from baseline. ISO-stressed 
N171-82Q mice had increased fractional shortening (FS), heart rate (HR), cardiac output (CO), 
and ejection fraction (EF) at trial days 5 and 12 relative to baseline, but there was no significant 
change in left ventricular mass (LV mass) (Figure 38A-C, F-G). Conversely, ISO-stressed WT 
animals showed significant LV mass increase from baseline at trial days 5 and 12, with 
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unchanged or no significant changes in FS, HR, CO, and EF at both time points (Figure 38A-C, 
F-G). ISO did not induce measurable changes in LVEDV or LVESV in either genotype (Figure 
38D-E). These results demonstrate that WT hearts employ a hypertrophic adaptation in response 
to chronic ISO stress, whereas HD hearts undergo sustained increase of heart rate and 
contractility but do not hypertrophy. 
To confirm limited hypertrophy as measured by echocardiography, I measured both gross 
heart mass and cardiomyocyte cross-sectional area post necropsy and tissue sectioning. 
Average heart mass/tibia length increased by 35.3% in WT animals treated with ISO relative to 
saline-treated WT controls and by a blunted 18.7% in HD animals treated with ISO relative to 
saline-treated HD controls (Figure 39). While I was not expecting to see any evidence of mass 
increase in hearts from stressed HD mice based on previous reports (87), this data reflects only 
the mice surviving to trial endpoint and therefore includes a survivor bias. Additionally, multiple 
factors besides hypertrophy can contribute to increased gross heart mass, so I examined 
cardiomyocyte cross-sectional area as a more sensitive measurement of heart hypertrophy. ISO 
induced robust cardiomyocyte cross-sectional area increase in WT mice relative to saline-treated 
controls, but it failed to increase the cross-sectional area of HD cardiomyocytes (Figure 40), thus 
confirming absence of a hypertrophic response in HD mouse hearts. 
Maladaptive cardiac changes are associated with fibrosis and cardiomyocyte death. I 
therefore stained heart sections with picrosirius red (Figure 41A-B) and Masson’s Trichrome 
(Figure 41C), and found that both WT and HD mice treated with ISO had increased fibrosis 
relative to saline treated animals, but the extent of fibrosis was significantly greater in HD hearts 
(Figure 41D). As fibrosis is compensatory to cardiomyocyte death, I next queried expression of 
genes encoding the apoptosis activator Bax and the anti-apoptotic factor Bcl2. Bax was 
moderately but significantly elevated in ISO-treated HD and WT hearts relative to saline controls 
and Bcl2 expression was decreased in stressed hearts, indicating that ISO stress promotes 
apoptosis in hearts from both genotypes (Figure 42). However, the differences in fibrosis infer 
82 
 
that stressed WT hearts likely have activated other anti-apoptotic activators, as pathologic 
changes are clearly less severe than in stressed HD animals. 
Decompensated heart failure occurs when maladaptive processes begin to impair cardiac 
function, which leads to increased pulmonary pressure and subsequent fluid accumulation in the 
lungs. The wet/dry lung mass ratio can therefore be used as an indicator of heart failure. 
Examination of the lungs from N171-82Q and WT mice treated with ISO or saline for 14 days 
showed no differences in wet/dry ratio between any group, suggesting that decompensated heart 
failure is not associated with any genotype-treatment combination at this time point (Figure 43). 
However, only lungs from animals that survived to the end of the trial were included in the 
analysis due to rapid, confounding, post-mortem lung changes.  
Given mTORC1’s role in adaptive hypertrophy, I measured mTORC1 indicators in the 
stressed hearts from both WT and HD animals that survived to trial endpoint. Interestingly, P-
S6/S6 levels were increased in ISO-stressed hearts from both genotypes, with notable variance 
in HD hearts (Figure 44A-B). P-4EBP1/4EBP1 levels were not different among treatment groups, 
but had a similar large variability observed in surviving stressed HD mice hearts (Figure 44A, C). 
These observations infer that partially overcoming the inherent cardiac mTORC1 dysregulation in 
HD mice may allow some adaptation and be associated with survival. 
Restoration of mTORC1 activity in HD hearts rescues stress adaptation 
The cardiac stress response in N171-82Q mice resembles that observed in other HD 
mouse models (85, 87), and is also similar to that of mTORC1-inhibited mice (121-123). I thus 
studied the relevance of mTORC1 inhibition in N171-82Q mouse hearts by selectively activating 
cardiac mTORC1. I utilized CT.AAV to express a constitutively active variant of Rheb (Rheb-
S16H, or simply caRheb) or GFP in HD mice hearts (165), and I confirmed transduction by 
western blot (Figure 45). Two weeks after vector delivery, I started ISO or saline infusion to 
induce heart stress as before. As expected, HD mice injected with CT.AAV.GFP and treated with 
ISO (GFP-ISO) experienced 40% mortality relative to saline-treated mice transduced with 
CT.AAV. GFP (GFP-saline) (Figure 46). In contrast, HD mice transduced with CT.AAV.caRheb 
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and treated with either isoprenaline or saline (caRheb-ISO and caRheb-saline, respectively) 
displayed only 5% mortality over the course of the study (Figure 46). Mortality rates among the 
HD mice in this experiment and the previous one are similar but not identical, and they are likely 
due to variation in overall cohort-to-cohort health. Despite the differences, this experiment shows 
that cardiac caRheb expression ameliorates sensitivity to ISO stress in HD mice.  
In addition to the decreased mortality, CT.AAV.caRheb injection restored functional 
elements of the cardiac stress response in HD mice on transthoracic echocardiogram. Imaging 
showed that mice in the GFP-ISO group had increased FS, HR, and EF from baseline without an 
increase in LV mass at trial days 5 and 12 (Figure 47A-C, G), similar to the observations made in 
stressed non-AAV-treated N171-82Q mice (Figure 38). Conversely, mice in the caRheb-ISO 
group responded to stress with an increase in LV size from pretreatment levels, with no changes 
in FS, HR, or EF from pretreatment levels at either time point (Figure 47A-C, G), approximating 
the WT response to chronic ISO (Figure 38). There were no measurable changes in LVEDV, 
LVESV, and CO for either vector (Figure 47D-F). These measurements collectively imply that 
caRheb transduction restores the functional elements of the adaptive stress response in HD 
hearts. 
I studied the effects of caRheb transduction on heart hypertrophy by examining heart 
mass/tibia length. There were no differences observed between mouse hearts from the GFP-
saline, GFP-ISO, and caRheb-saline groups. However, caRheb-ISO treated HD mice 
experienced a 27.5% increase in heart mass/tibia length (Figure 48), implying mTORC1 
activation successfully permitted heart hypertrophy in response to stress. This conclusion was 
confirmed by analysis of cardiomyocyte cross-sectional area, which showed that mice in the 
caRheb-ISO group experienced robust cross-sectional area increase relative to all other groups, 
representing restored hypertrophic adaptation (Figure 49). As predicted, there was no difference 
in cardiomyocyte mean cross-sectional area between the GFP-saline and GFP-ISO groups 
(Figure 49). Mice in the caRheb-saline group had moderately increased cardiomyocyte cross-
sectional area relative to the GFP-saline group, an expected finding given mTORC1’s role in 
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promoting growth, but probably too subtle to be observed on echocardiography (Figure 49). 
These analyses clearly indicate that restoring cardiac mTORC1 activity in HD mice permits 
adaptive heart hypertrophy with ISO stress. 
The impact of caRheb on restoring adaptive hypertrophy and preventing stress-related 
pathologic changes in N171-82Q hearts was apparent in analyses of fibrosis by picrosirius red 
(Figure 50A-B) and Masson’s trichrome stains (Figure 50C). Extensive fibrosis was present in 
HD mouse hearts from the GFP-ISO group, whereas fibrosis in hearts from the caRheb-ISO 
group was comparatively mild (Figure 50D). Thus, caRheb expression successfully decreases 
pathological changes in N171-82Q hearts. Interestingly, qPCR analysis of apoptotic factors 
showed moderately but significantly increased Bax expression in hearts from the caRheb-ISO 
group only, and no significant changes in Bcl2 expression (Figure 51), though considering the 
differences in fibrosis this probably reflects a survivor bias more than it does ongoing apoptosis.  
Similar to before, wet/dry lung mass ratios of mice surviving to trial endpoint were not 
different between groups, suggesting that the mice included in the analysis were not experiencing 
decompensated heart failure at the time of observation (Figure 52). Additionally, as before, 
mTORC1 activity in hearts of surviving animals was increased with ISO treatment (Figure 53A-
C). While P-S6/S6 levels in caRheb-transduced mice groups trended higher than their respective 
GFP-transduced mice groups, they did not achieve statistical significance due in part to large 
variance in GFP-ISO samples (Figure 53B). These results thus support the hypothesis that the 
ability to overcome dysregulated cardiac mTORC1 activity in HD hearts, through endogenous or 
exogenous means, is associated with survival in response to stress. 
HD mouse hearts have impaired autophagy and mitochondrial biogenesis 
Cardiac mTORC1 dysregulation in HD mouse hearts clearly impairs adaptation to stress 
and may therefore explain heart disease-related mortality in HD patients. mTORC1, though, 
regulates many different molecular pathways, and they may not all contribute equally to stress 
sensitivity in HD mice. Deletion of cardiac mTor in adult mice had a severe and fatal phenotype 
but was largely rescued with 4ebp1 deletion, suggesting that global protein synthesis is the 
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critical molecular mechanism in the adaptive stress response (121). Alternatively, HD mouse 
hearts had decreased ATP and a shift away from oxidative metabolism, suggesting that 
mitochondrial function may be the key inhibitory condition (91). Understanding which downstream 
mechanisms contribute most to the impaired stress response could help guide future therapeutic 
strategies in a manner that limits adverse effects. 
In order to better understand the molecular consequences of mTORC1 dysregulation in 
HD hearts, I made preliminary studies of two cellular mechanisms regulated by mTORC1, 
autophagy and mitochondrial biogenesis. Autophagy, is a cellular process to dispose of and 
recycle old, improperly folded, or nonfunctional cellular machinery (166) and is canonically 
inhibited by mTORC1. Consequently, small molecule mTORC1 inhibitors are frequently used as a 
means of promoting autophagy for experimental purposes (167, 168). Despite dysregulated 
mTORC1 activity in the brain, HD is associated with decreased autophagy (130). In order to 
examine autophagy in HD mouse hearts I measured post-translational modification of LC3, a 
component of autophagic vesicles that is cleaved from its pro-form to LC3-I, then lipidated to the 
mature LC3-II. Previous work has shown that LC3-II levels correlate with the number of 
autophagic vesicles within a cell, and LC3-II therefore serves as a crude indicator of autophagy 
(169). In N171-82Q mouse hearts, LC3-II was increased at 6 weeks of age, consistent with 
decreased mTORC1, but normalized with disease progression and then decreased relative to WT 
at 18 weeks of age and in zQ175 hearts at 12 months of age (Figure 54A-B). Levels of the LC3-
pro and LC3-I followed a pattern opposite LC3-II: both increased in N171-82Q heart lysates 
starting at 10 weeks of age for LC3-Pro and 14 weeks of age for LC3-I (Figure 54A, C-D). These 
changes suggest attenuated autophagy in late-stage HD hearts despite low levels of mTORC1 
activity, which may result from impaired initiation or inhibited degradation of autophagic vesicles 
(flux). To distinguish between the two, I measured protein levels of SQSTM1/p62 and Beclin-1. 
The only difference I found occurred in 14 week-old N171-82Q mice, at which point p62 levels 
were mildly elevated, but the magnitude was low and it is therefore probably not physiologically 
relevant (Figure 55A-C). In HD hearts, then, autophagic flux does not appear to be impaired, so 
limited autophagic initiation via an mTORC1-independent mechanism is the more likely 
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explanation. However, further investigation must be undertaken to confirm this hypothesis, as well 
as to understand its functional relevance. 
Another potential mechanism affected by mTORC1 dysregulation is mitochondrial 
biogenesis, a process mediated by the transcription factor and mTORC1 target peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) (116). In HD brains, PGC-1α 
expression and many of its downstream target genes were downregulated relative to WT, and 
restoration of mTORC1 activity improved those abnormalities (24, 130). With similar mTORC1 
dysregulation between the heart and brain in HD mice, and mitochondrial abnormalities 
implicated in HD mouse hearts (37, 91), I expected to find decreased cardiac Pgc-1α levels. 
Surprisingly, expression of Pgc1α and its co-transcription factor Nrf1 was increased relative to 
WT in N171-82Q hearts starting at 14 weeks of age (Figure 56A-B). Nrf1 was also mildly but 
significantly upregulated in 12 month-old zQ175 mouse hearts. However, expression of Pgc-
1α/Nrf1 downstream target genes did not follow the same pattern: Tfam and Idh3a levels in HD 
hearts were equal to WT except in N171-82Q mouse hearts at 10 weeks, at which point they 
were decreased (Figure 56C-E). Atp5g1 levels were also lower in both 10 week-old and 14 
week-old N171-82Q mouse hearts. The resulting relationship between Pgc-1α expression and 
one of its downstream target Idh3a (Figure 56F) suggests that cardiomyocytes may be struggling 
to maintain expression of functional mitochondrial proteins (Idh3a and Atp5g1), and the rising 
levels of Pgc-1α and Nrf1 may be an attempt at compensation. This process appears to occur 
independent of mTORC1 activity, but further work is necessary before any conclusions can be 
made. 
Discussion 
In the heart, mTORC1 mediates adaptive hypertrophy, so its dysregulation in HD mouse 
hearts may result in decreased compensation and increased sensitivity to stress. In this chapter I 
show that symptomatic N171-82Q and zQ175 mice have increased mortality when continuously 
infused with isoprenaline for 14 days. On echocardiogram HD mice have increased rate and 
contractility throughout the trial but do not experience increased LV mass; conversely, WT mice 
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have increased LV mass evident by trial day 5 but have normal rate and contractility. Post-
mortem analysis showed that ISO-stressed N171-82Q mouse hearts fail to hypertrophy and have 
increased fibrosis relative to stressed WT hearts. Importantly, these phenotypes were reversed in 
N171-82Q mice injected with CT.AAV.caRheb, showing that restoration of cardiac mTORC1 in 
HD animals allows adaptation to stress and prevents pathologic changes. These studies thus 
conclude that one of the main HD heart phenotypes is increased sensitivity and impaired 
adaptation to stress, and the molecular mechanism underlying it is cardiac mTORC1 
dysregulation. 
One of the most interesting, unanswered questions in the cardiac stress studies is why 
do stressed HD mice die? Arrhythmias related to chronic adrenergic stimulation is one potential 
explanation (170), but the amount of fibrosis in stressed HD mouse hearts suggests a less acute, 
pathogenic process.  Echocardiography showed that HD mouse hearts respond to the chronic 
ISO by maintaining a sustained increase in rate and contractility, which is the response expected 
with acute adrenergic stimulation, but it is atypical after 5 or 12 days of chronic treatment. 
Adaptive hypertrophy is a key mechanism in improving myocardial efficiency and decreasing 
energy expenditure: applying Laplace’s law, increasing the ventricular wall thickness decreases 
wall tension, and therefore decreases the amount of work required with each contraction (159, 
171). Thus, in the absence of adaptive hypertrophy, stressed HD hearts exist in a state of high 
energy usage and become susceptible to exhaustion. Indeed, I found qualitatively that most of 
the myocardial fibrosis was at the areas furthest from coronary blood supply, occurring in a 
pattern similar to ischemic injuries associated with maladaptive heart hypertrophy (82). In 
stressed HD mouse hearts, impingement of small coronary vessels by excessive cardiac tissue is 
unlikely, but it may be that the tissue’s oxygen usage is so high that even healthy coronary 
arteries cannot meet the demands. The exhaustion hypothesis is strengthened by the evidence 
pointing to mitochondrial abnormalities in HD hearts (91): in a state of high energy expenditure, 
impaired energy production would be detrimental. Ideally, metabolic testing of ex vivo perfused 
hearts coupled with sensitive measurements of various energy-associated molecules such as 
ATP, ADP, and creatinine in stressed HD hearts could help confirm this hypothesis. 
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Many of the analyses are confounded by a survivor bias. Attrition almost always occurred 
before humane end points could be assessed, and though histologic characteristics examined 
here were typically preserved after a significant post-mortem interval, RNA expression, lung fluid, 
and protein phosphorylation were generally degraded. Thus, the wet/dry lung mass ratios 
reported here may not have differed because all of the mice that went into decompensated heart 
failure died before they could be euthanized and tissues collected (lungs that were collected from 
animals that died in situ were found to be too degraded to provide accurate fluid level 
assessment). Additionally, for both N171-82Q and zQ175 mice, mortality occurred almost entirely 
within the first half of the trial. As a result, the 40-50% of ISO-treated HD mice that survived must 
have been able to mount some sort of adaptive response, which could have confounded results. 
This subpopulation does raise interesting questions, such as what mechanisms allowed survival 
in spite of a baseline mTORC1 dysregulation? Given the severe and rapid mortality in 18 month-
old zQ175 mice, it is likely that age-related mechanisms are a major component. Future work 
should be directed at clarifying both the end-of-life phenotype for the HD mice that don’t survive 
chronic ISO-stress, and understanding how other HD mice do survive. 
One of the most exciting findings from these studies is clarification of an HD-related heart 
phenotype that can focus epidemiological and other clinical studies. While heart disease is a 
common cause of death for HD patients, it is also a common cause of death for the general 
population. These studies suggest that HD many not be associated with an increased incidence 
of heart disease. However, if an HD patient develops any form of chronic cardiovascular 
disease—as a result of lifestyle, genetics, etc.—it may progress to heart failure and death far 
more quickly than in unaffected individuals. 
Materials and Methods 
Animals 
As in other chapters, all animal protocols were approved by the Animal Care and Use 
Committee at The Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous 
zQ175 HD murine model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and 
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maintained on a B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped 
using primers specific for human HTT, and age-matched WT littermates were used as controls for 
all experiments. All experiments were performed with male mice exclusively. Animals were 
housed in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food 
and water were provided ad libitum. 
Cardiac Stress Induction 
Cardiac stress was induced by constant infusion of isoprenaline (ISO, also known as 
isoproterenol, Sigma) using osmotic minipumps (Alzet). ISO was administered at a dose of 30 
mg/kg/day for 14 days. Pumps were filled using sterile procedures and primed in sterile PBS at 
37°C for 24 hours prior to implantation. ISO administration was started at 12 weeks of age for 
N171-82Q mice and 18 months of age for zQ175 mice. Implantation procedure followed 
manufacturer’s recommended protocol and was performed using sterilized equipment. Briefly, 
mice were anesthetized using isoflurane and placed in the prone position. The subscapular 
region of the back was shaved and cleaned, and a small, subcutaneous, horizontal incision was 
made at midline just caudal to the scapulae. A closed hemostat was inserted caudally about 1 
inch, gently opened about 1 cm, and withdrawn, disrupting connective tissue bonds and forming a 
small pocket for the pump. While ideally the pump should sit midline, in early experiments it 
always drifted to one side; thus, in later trials the pocket was angled towards the mouse’s right 
side in order to prevent distorting the optimal window for echocardiography. The pump was 
inserted with the flow regulator pointed caudally so as to avoid drug leakage out of the incision. 
The incision was close with wound clips, which were removed 7-10 days after surgery. 
Transthoracic Echocardiography 
Similar to echocardiography in chapter 2, all echo procedures were performed at the 
CHOP Small Animal Imaging Facility.  Mice were anesthetized with 2.5% isoflurane and 
positioned on a heated stage with continuous EKG measurement. Transthoracic 
echocardiograms were recorded using an MS-400 30 MHz probe connected to a Vevo 2100 or 
3100 imager with cardiovascular measurement package. (Fujifilm VisualSonics). Parasternal long 
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axis views with Doppler were used to calculate aortic ejection time and mitral valve flow 
dynamics. Parasternal short axis M-mode views at the level of papillary muscles were used to 
calculate posterior wall, septum, and ventricular diameter each at end diastole and end systole. 
Images were acquired and dimensions measured by Christine J. Pascua, an experienced 
operator blinded to mouse genotype. Stroke volume was calculated as the difference between left 
ventricular end diastolic and systolic volumes, and cardiac output calculated as the stroke volume 
multiplied by the heart rate. 
Heart Mass Analysis 
Mice were massed, then anesthetized with a mixture of ketamine/xylazine (IP injection of 
100 mg/kg and 10 mg/kg, respectively) and transcardially perfused with cold saline. Unlike 
previously, hearts were excised and atria removed before being blot-dried and massed on an 
analytical balance. Left tibias were removed and measured with electronic calipers to control for 
variation in total body size. 
Western Blots 
For in-depth western blot protocol, see Chapter 3: Materials and Methods. Briefly, protein 
was extracted from heart samples using RIPA buffer and total protein concentration was 
determined by BCA (Pierce). 30 µg of protein was reduced and separated by SDS-PAGE on 12% 
bis-tris polyacrylamide gels in MOPS buffer (Bio-Rad), then transferred to 0.2 µm PVDF (Bio-
Rad). Antibodies used are described in Table 4. Blots were developed using ECL Plus Western 
Blotting Detection System (GE Healthcare) and imaged digitally on a ChemiDoc MP imaging 
system (Bio-Rad). Blots were stripped no more than two times using Restore Stripping Buffer 
(Thermo) for 9 minutes at 37°C. Densitometry was performed using NIH ImageJ software. 
Densities of bands detected by phospho-antibodies were normalized to densities of bands 
detected by phospho-independent antibodies in same lane. Phospho-independent antibody 
densities were normalized to αTubulin or Na/K-ATPase band in same lane. 
Histology 
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As before, excised hearts were bisected transversely at the approximate midpoint, and 
apical portions were post-fixed overnight in 4% paraformaldehyde. Heart tissue was dehydrated 
and embedded in paraffin by the CHOP Pathology Core, and sectioned to 5-7 µm on a rotary 
microtome (Microm HM 355s). Mounted sections were heated at 56-60°C for 20 minutes to 
remove excess paraffin, flatten sections, and prevent detachment. Sections were allowed to cool 
to RT and rehydrated before continuing with staining procedures. All sections were imaged on a 
Leica DM6000B light microscope. 
Wheat germ agglutinin: sections were washed twice for two minutes in tap water, then 
placed into a solution of 10 µg/ml wheat germ agglutinin and 2 µg/ml Hoechst stain in 
PBS. Slides were stained for 15 minutes at 37°C, then washed twice for two minutes in 
deionized water and mounted with fluorogel. For quantitative analysis, images were taken 
throughout the posterior wall to encompass all transversely-sectioned cells. ImageJ was 
used to overlay a grid on each image to randomly select approximately 50 cells/image 
and cross-sectional area was measured for each selected cell by either manually 
circumscribing the cell exterior or using the threshold function and magic wand tool. At 
least 200 cells were measured per heart.  
Masson’s Trichrome stain: sections were incubated in 56°C Bouin’s solution (Sigma) for 
10 minutes, followed by staining with Masson’s Trichrome (Sigma) according to standard 
procedure. Briefly, tissues were stained with working Weigert’s iron hematoxylin for 5 
minutes, rinsed in deionized water, and then stained in Biebrich scarlet-acid fuchsin for 5 
minutes. Slides were rinsed in deionized water, fixed in working 
phosphotungstic/phosphomolybdic acid solution for 5 minutes, and then immediately 
stained with aniline blue solution for 5 minutes. Sections were destained in 1% acetic 
acid for 2 minutes, rinsed in deionized water, dehydrated through ethanol, cleared in 
xylene, and mounted.  
Picrosirius Red stain: slides were stained with Weigert hematoxylin (Sigma) for 8 
minutes, rinsed for 10 minutes in running tap water, then incubated for 1 hour in a 0.1% 
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solution of Direct Red 80 (Sigma) in saturated aqueous picric acid (1.3%). Destaining 
was accomplished by incubating slides in two rinses of 0.5% aqueous acetic acid for 1 
minute each. Slides were then dehydrated through ethanol, cleared in xylene, and 
mounted with DPX. Low-power images were taken using both a standard bright field filter 
and a polarizing filter. At least 9 images were collected per heart, intended to capture a 
large section of the left ventricle. Large vessels were avoided because of their high 
collagen content. ImageJ was used to threshold and measure area of each image, and 
percent of total area occupied by fibrotic tissue was calculated by dividing the area of the 
polarized image by the area of the standard image. 
Quantitative PCR 
For in-depth explanation of qPCR protocol, see Chapter 2: Materials and Methods. 
Briefly, RNA was extracted from snap-frozen mouse hearts using Trizol (Ambion). cDNA libraries 
were constructed from 2 µg RNA template using with random hexamer primers and a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green qPCR was 
performed using either custom-designed primer sets, or pre-designed and validated primer sets 
purchased from IDT. Genes that utilized pre-designed primers sets in this chapter include: Nrf1, 
Idh3a, and Atp5g1. For custom-designed primer sets used in this chapter, see Table 5. Data was 
analyzed using either the 2-ΔΔCt method, or by creating a standard curve from known 
concentrations of plasmid DNA each containing a single copy of the gene of interest. 
Statistical Analyses 
Survival curves were analyzed by Mantel-Cox (Log-Rank) test. Echocardiography data 
was analyzed by one-way ANOVA with Sidak’s multiple comparison test. All other data was 
analyzed by one-way ANOVA with Tukey’s post-hoc analysis or Student’s T-test. For all statistical 
analyses p ≤ 0.05 was considered significant. All statistics were performed in GraphPad Prism 
version 7. 
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Table 4: Antibodies used for Chapter 4 
Company  Antigen Product ID WB Dilution 
Cell Signaling P-S6 (ser235/236) 4858 1:1000 
 S6 2217 1:1000 
 P-4EBP1 (ser65) 9451 1:500 
 4EBP1 9644 1:1000 
 P-Akt (ser473) 4060 1:500 
 Akt  4691 1:1000 
 P-mTOR (ser2448) 5536 1:500 
 mTOR  2983 1:1000 
 Rheb 13879 1:1000 
Abgent LC3 APG8B 1:500 
AbCam Beclin 1 ab207612 1:2000 
 SQSTM/p62 ab56416 1:1000 
Thermo Fisher GFP A11122 1:1000 
Sigma αTubulin T5168 1:2000 
GE Healthcare Anti-mouse HRP NA931 1:20,000 
 Anti-rabbit HRP NA934 1:15,000 
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Table 5: Custom Primers for Chapter 4 
Gene Name Forward Primer Reverse Primer 
Bax GCAGCTGACATGTTTGCTGATG AGCCCATGATGGTTCTGATCAG 
Bcl2 AGCCTGAGAGCAACCCAATG CGGTAGCGACGAGAGAAGTC 
Pcg1α CTATGCAGACCTAGATACCAACTC GCTTCTCTGAGCTTCCTTCAG 
Tfam AGAAAGCACTGGTAAAGAGAAGAG TGAGCCGAATCATCCTTTGC 
Tbp TACCGTGAATCTTGGCTGTAAAC GTTGTCCGTGGCTCTCTTATTC 
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Figure 36: N171-82Q mice have increased mortality to ISO stress. 
Survival curves of N171-82Q and age-matched WT littermates treated with continuous 
ISO or saline infusion for 14 days starting at 12 weeks of age. For each group n ≥ 8. N171-82Q 
mice experience approximately 50% mortality during the trial period, compared to 15% mortality 
in saline-treated HD animals and 0% in either WT treatment group. Mantel-Cox (Log-Rank) test, 
**p ≤ 0.01. 
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Figure 37: ISO stress causes increased mortality in zQ175 mice. 
Survival curve of 18 month-old heterozygous zQ175 mice and age-matched WT 
littermates treated with continuous ISO or saline infusion for 14 days. n ≥ 7 for all groups. 
Stressed zQ175 mice experienced approximately 83% mortality over the course of the study, 
whereas stressed WT mice experienced 25% mortality. Increased mortality in mice of both 
genotypes demonstrates the effect of age on ability to respond to stress. Mantel-Cox (Log-Rank) 
test, **p ≤ 0.01. 
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Figure 38: HD hearts have increased rate and contractility with chronic ISO stress. 
Echocardiographic measurements in N171-82Q mice and WT littermates infused with 
continuous ISO or saline for 14 days starting at 12 weeks of age. Graphs are depicted as change 
from day 0 baseline echoes and represent: (A) left ventricular mass (LV mass), (B) fractional 
shortening (FS), (C) heart rate (HR), (D) left ventricular end diastolic volume (LVEDV), (E) left 
ventricular end systolic volume, (F) cardiac output (CO), and (G) ejection fraction (EF). n ≥ 5 for 
all groups. ISO-stressed WT hearts gain LV mass but have normal FS and HR; ISO-stressed HD 
hearts have normal LV heart mass but have increased FS, HR, CO, and EF, indicating increased 
contractility and rate. Error bars represent SEM. One-way ANOVA with Sidak’s multiple 
comparison analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 39: ISO-stressed HD hearts have blunted gross mass increase. 
Comparison of heart mass-to-tibia length ratio in N171-82Q and WT littermates at 12 
weeks of age treated with either continuous ISO or saline infusion for 14 days. Stressed WT 
hearts experience 35% mass increase relative to saline-treated WT hearts. Stressed HD hearts 
experience only 17% mass increase relative to unstressed HD hearts, suggesting a blunted 
response. Note that only mice that survived to trial endpoint were included in the analysis. n ≥ 7 
for each group. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 
0.05, ***p ≤ 0.001. 
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Figure 40: HD mouse cardiomyocytes do not hypertrophy in response to ISO stress. 
Wheat germ agglutinin staining and measurement of cross-sectional area in heart 
sections taken from N171-82Q and WT littermates treated with either ISO or saline for 14 days 
starting at 12 weeks of age. ISO-stressed WT mice had a significant increase in cardiomyocyte 
cross-sectional area relative to saline treated WT mice, whereas cardiomyocyte cross-sectional 
area was not different between stressed and unstressed HD mice. N ≥ 7 hearts for each group, n 
≥ 200 cells measured per heart. Scale bars = 20 µm. Error bars represent SEM. One-way 
ANOVA with Tukey’s post-hoc analysis, **p ≤ 0.01. 
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Figure 41: Stressed HD hearts are more fibrotic than stressed WT hearts. 
Representative staining and quantitation of fibrosis in heart sections from N171-82Q mice 
and WT littermates treated with continuous ISO or saline for 14 days starting at 12 weeks of age. 
(A-B) Picrosirius red stain: fibrotic tissue (A) stains bright red using standard bright field 
techniques, and (B) is birefringent when viewed through a polarizing filter. (C) Masson’s trichrome 
stain: cellular proteins stain red, nuclei stain black, and fibrotic tissue stains bright blue. (D) 
Quantitation of fibrosis expressed as percent area occupied by fibrotic tissue using picrosirius red 
images. N ≥ 12 hearts for each group, n ≥ 9 images per heart. Scale bars = 100 µm. Error bars 
represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, ***p ≤ 0.001. 
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Figure 42: ISO-stressed mouse hearts have pro-apoptotic gene expression changes. 
Quantitative PCR analysis of genes associated with apoptosis in hearts from N171-82Q 
and WT mice treated with ISO or saline for 14 days starting at 12 weeks of age. (A) Expression of 
the pro-apoptotic gene Bax, and (B) expression of the anti-apoptotic gene Bcl2. Stressed hearts 
from both WT and HD mice have increased Bax expression and decreased Bcl2 expression 
relative to unstressed hearts of the same genotype, suggesting that stress promotes apoptosis 
regardless of genotype. However, expression changes, while statistically significant, are relatively 
mild. Tbp was used as an internal control and data are graphed relative to expression in hearts 
from saline-treated WT mice. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc 
analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 43: Decompensated heart failure is not occurring in ISO-treated mice. 
Wet/dry lung mass ratio in ISO- or saline-treated N171-82Q or WT mice at after 14 days 
of treatment starting at 12 weeks of age. Increased wet/dry lung ratio results from fluid backup 
due to inefficient LV function and is indicative of decompensated heart failure. There were no 
differences between any of the treatment groups, suggesting that at this time point heart failure is 
not occurring. Note that the data here do not include mice that died before trial endpoint. n ≥ 7 for 
all groups. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis. 
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Figure 44: mTORC1 activity is increased in hearts from stressed HD mice. 
(A) Representative western blot lanes and quantitation of (A) P-S6 levels and (B) P-
4EBP1 levels in hearts from N171-82Q and WT mice treated with ISO or saline for 14 days 
starting at 12 weeks of age. n ≥ 7 for each group. P-S6 levels were increased in ISO-stressed HD 
mouse hearts relative to unstressed HD and WT hearts. Note that these data include only mice 
that survive to trial endpoint, so an endogenous ability to overcome decreased mTORC1 activity 
in response to stress may be associated with better survival outcomes. Error bars represent 
SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05. 
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Figure 45: Confirmation of caRheb and GFP transduction in HD mouse hearts. 
Western blot confirmation of caRheb (R) or GFP (G) expression in hearts from N171-82Q 
mice injected with either CT.AAV.GFP or CT.AAV.caRheb. caRheb is FLAG-tagged, resulting in 
increased molecular mass relative to endogenous Rheb. 
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Figure 46: Cardiac caRheb expression prevents ISO-related mortality in HD mice. 
Survival curves of N171-82Q mice injected with CT.AAV.GFP or CT.AAV.caRheb, then 
treated with continuous infusion of ISO or saline for 14 days starting at 12 weeks of age. ISO-
stressed mice expressing GFP treated experienced 40% mortality by study end point compared 
to only 5% in stressed mice expressing caRheb. Thus, restoring mTORC1 activity in HD mouse 
hearts rescues stress-associated mortality. n ≥ 12 for all groups. Mantel-Cox (Log-Rank) test, **p 
≤ 0.01. 
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Figure 47: Cardiac caRheb expression restores normal stress adaptation in HD hearts on 
echocardiography. 
Transthoracic echocardiography measurements in N171-82Q mice injected with 
CT.AAV.caRheb or CT.AAV.GFP and treated with ISO or saline for 14 days starting at 12 weeks 
of age. n ≥ 4 for each group. Data are graphed as changes from day 0 (baseline) measurements 
and include: (A) LV mass, (B) FS, (C) HR, (D) LVEDV, (E) LVESV, (F) CO, and (G) EF. Similar to 
before, HD mice expressing GFP experience do not have increased LV mass but experience 
increased FS, HR, and EF in response to ISO treatment. Conversely, HD mice expressing 
caRheb experience increased LV mass in response to ISO treatment, but have normal FS and 
HR, thus replicating the WT phenotype. Error bars represent SEM. One-way ANOVA with Sidak’s 
multiple comparison analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 48: caRheb expression in HD mouse hearts permits hypertrophy in response to 
stress. 
Heart mass-to-tibia length ratio in N171-82Q mice injected with CT.AAV.caRheb or 
CT.AAV.GFP and treated with ISO or saline for 14 days starting at 12 weeks of age. In caRheb-
expressing mice treated with saline, heart mass-to-tibia length ratio increased by 27% relative to 
GFP-expressing mice treated with saline. Thus, gross size analysis shows restoration of the 
hypertrophic response following mTORC1 activity activation. One-way ANOVA with Tukey’s post-
hoc analysis, ***p ≤ 0.001. 
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Figure 49: Cardiac caRheb expression in HD mice restores ISO-induced cardiomyocyte 
hypertrophy. 
Wheat germ agglutinin staining and measurement of cardiomyocyte cross-sectional area 
in heart sections from N171-82Q mice injected with CT.AAV.caRheb or CT.AAV.GFP and treated 
with ISO or saline for 14 days starting at 12 weeks of age. Cardiomyocyte cross-sectional area 
was equal between saline- and ISO-treated GFP-expressing mice. There was a slight but 
significant increase in cardiomyocyte cross-sectional area in saline-treated caRheb-expressing 
mice relative to saline-treated GFP-expressing mice, and there was a robust increase in 
cardiomyocyte cross-sectional area of ISO-treated caRheb-expressing mice compared to all other 
treatment groups. Thus, restoration of mTORC1 activity in HD mouse hearts restores the ability to 
hypertrophy in response to ISO stress. N ≥ 7 hearts for each group, n ≥ 200 cells measured per 
heart. Scale bars = 20 µm. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc 
analysis, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 50: Cardiac caRheb expression prevents ISO-induced fibrosis in HD mouse hearts. 
Representative staining and quantitation of fibrosis in heart sections from N171-82Q mice 
injected with CT.AAV.caRheb or CT.AAV.GFP treated with continuous ISO or saline for 14 days 
starting at 12 weeks of age. (A-B) Picrosirius red stain: fibrotic tissue (A) stains bright red using 
standard bright field techniques, and (B) is birefringent when viewed through a polarizing filter. 
(C) Masson’s trichrome stain: cellular proteins stain red, nuclei stain black, and fibrotic tissue 
stains bright blue. (D) Quantitation of fibrosis expressed as percent area occupied by fibrotic 
tissue using picrosirius red images. N ≥ 8 hearts for each group, n ≥ 9 images per heart. Scale 
bars = 100 µm. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, ***p 
≤ 0.001. 
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Figure 51: ISO stress induces mild pro-apoptotic gene expression in HD hearts expressing 
caRheb. 
Quantitative PCR analysis of genes associated with apoptosis in hearts from N171-82Q 
injected with CT.AAV.caRheb or CT.AAV.GFP and treated with ISO or saline for 14 days starting 
at 12 weeks of age. (A) Expression of the pro-apoptotic gene Bax, and (B) expression of the anti-
apoptotic gene Bcl2. Bax expression was increased only in hearts from ISO-treated caRheb-
expressing mice, and Bcl2 was not different among any of the treatment groups. Note that only 
mice that survived to trial endpoint are included in this analysis. Tbp was used as an internal 
control and data are graphed relative to expression in hearts from saline-treated CT.AAV.GFP-
injected mice. n ≥ 5 for each group. Error bars represent SEM. One-way ANOVA with Tukey’s 
post-hoc analysis, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 52: Heart failure is not occurring in ISO-stressed HD mice injected with either 
CT.AAV.GFP or CT.AAV.caRheb. 
Wet/dry lung mass ratio in ISO- or saline-treated N171-82Q mice after 14 days of 
treatment starting at 12 weeks of age following injection with CT.AAV.caRheb or CT.AAV.GFP. 
There were no differences between any of the treatment groups, suggesting that at this time point 
heart failure is not occurring. Note that the data here do not include mice that died before trial 
endpoint. n ≥ 5 for all groups. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc 
analysis. 
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Figure 53: ISO stress promotes mTORC1 activity in HD mice injected with either 
CT.AAV.caRheb or CT.AAV.GFP. 
(A) Representative western blot and quantitation of (B) P-S6 and (C) P-4EBP1 levels in 
hearts from N171-82Q mice injected with CT.AAV.caRheb or CT.AAV.GFP and treated with ISO 
or saline for 14 days starting at 12 weeks of age. P-S6 levels are increased in hearts from ISO-
stressed mice injected with either vector. P-4EBP1 levels are increased only in hearts from 
stressed HD mice expressing caRheb. Only mice that survived to trial endpoint, so data imply that 
overcoming the decreased mTORC1 activity with stress in HD mice may be associated with 
survival. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001. 
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Figure 54: LC3 processing decreases with disease progression in HD mouse hearts. 
(A) Representative western blot and quantitation of (B) LC3-II, (C) LC3-Pro, and (D) LC3-
I levels in hearts from N171-82Q and WT mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) 
weeks of age, and in zQ175 mice and WT littermates at 12 months of age (n ≥ 10). At 6 weeks, 
N171-82Q mice have increased LC3-II and normal LC3 precursors, consistent with increased 
autophagy. As disease progresses, however, LC3-II levels first normalize then decrease relative 
to WT, concomitant with an increase in LC3-Pro starting at 10 weeks of age and an increase in 
LC3-I starting at 14 weeks of age. In 12 month-old zQ175 mice, both LC3-II an LC3-I are 
decreased relative to WT. Together these data suggest that in young HD mice autophagy is 
increased, consistent with decreased mTORC1 activity. However, as mice get older and disease 
progresses, autophagy gradually slows down and is inhibited by an mTORC1-independent 
pathway. Band densities were normalized to density of αTubulin band in the same lane. Data are 
graphed relative to WT for each time point and error bars represent SEM. Student’s T-test, *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 55: Autophagy-associated protein levels are not affected in HD mouse hearts. 
(A) Representative western blot with densitometry quantitation of (B) p62 levels and (C) 
Beclin1 levels in N171-82Q and WT mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 
8) weeks of age, and in zQ175 and WT mouse hearts at 12 months of age (n ≥ 10). P62 levels 
are mildly increased in 14 week-old N171-82Q mouse hearts, but the magnitude is unlikely to be 
physiologically relevant. Otherwise, no differences are observed between HD and WT at any time 
point. Thus, autophagic flux may not be affected in HD mouse hearts. Error bars represent SEM. 
Student’s T-test, **p ≤ 0.01. 
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Figure 56: PGC1α signaling is altered in HD mouse hearts 
Quantitative PCR analysis of genes regulated by mTORC1 and associated with 
mitochondrial biogenesis in N171-82Q and WT mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n 
≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10): (A) Pgc1α, (B) Nrf1, (C) 
Tfam, (D) Idh3a, (E) Atp5g1. (F) is a comparison of Pgc1α expression with that of Idh3a, one of 
its downstream target genes. Pgc1α and its co-transcription factor Nrf1 are both upregulated in 
N171-82Q mice starting at 14 weeks; Nrf1 is also upregulated in 12 month-old zQ175 mice. 
However, expression of their immediate target Tfam and further downstream genes are only 
different from WT at 10 weeks in N171-82Q mice, at which point they are downregulated to WT. 
Tbp was used as an internal control. Data is graphed relative to WT for each time point and error 
bars represent SEM. Student’s T-test, *p ≤ 0.05, **p ≤ 0.01.  
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
The vast majority of Huntington’s disease research justifiably focuses on its neurologic 
phenotypes: profound neurodegeneration, particularly within the striatum, is a hallmark of the 
disease that explains its most characteristic and severe signs and symptoms (1). Multiple 
therapeutic strategies have been attempted since the discovery of the HTT gene, but, as with 
most other genetic diseases, a cure has so far remained elusive. Fortunately, recent progress in 
gene therapy approaches have led to the promise of a cure for HD (33, 35), though the nature of 
the therapy requires limiting distribution to the CNS. Thus, the peripheral effects of mHTT 
expression will still need to be addressed. HD patients experience a myriad of phenotypes 
outside the CNS, including increased peripheral inflammation, cardiac abnormalities, weight loss, 
skeletal muscle dysfunction, and metabolic abnormalities (172). Understanding and treating these 
signs and symptoms can lead to profound quality of life improvements for HD patients, and some 
of them have even been shown to have a direct effect on disease progression (173). 
Furthermore, HTT-targeting gene therapies within the CNS will unmask these peripheral 
phenotypes and present new clinical challenges. 
An association between heart disease and HD has existed since before the discovery of 
the HTT gene (40, 42), but the phenotype has not been well studied. Many of the clinical studies 
that examine the heart in HD are limited by small patient numbers and noninvasive edge-of-bed 
analyses (47-51). Multiple factors contribute to this gap, including, significantly, the large number 
of participants needed to account for confounding factors associated with heart disease in large, 
observational studies (43)—a major challenge when studying a rare disease like HD. Other 
limitations to understanding the heart in HD are self-imposed, such as exclusion of patients with 
history of heart disease from HD-specific studies, failure to record cardiovascular measurements 
in large, observational studies and databases, and the difficulty/expense of obtaining post-
mortem tissue samples.  
As a result of the limitations surrounding heart research in HD patients, most 
understanding of the HD heart phenotype is inferred from mouse models. However, only a 
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handful of such studies have been published to date, many of them simply descriptive studies 
highlighting the characteristics unique to different HD mouse models (37, 83, 85, 86). Very few 
studies aimed to determine the mechanisms underlying the noted cardiac phenotypes common 
across HD mouse lines (91). Thus, the work I present in this thesis is significant because I 
propose that cardiac mTORC1 dysregulation in HD impairs adaptive hypertrophy and thus 
increases mortality with cardiac stress. While these studies were performed in mice, they provide 
shape and focus to future epidemiological and clinical studies and raise questions that can be 
answered with the patient-centered tools available. 
The statistics from death certificates citing heart disease as the second leading cause of 
death should be interpreted cautiously for several reasons (40-42). First, the accuracy of the 
death certificate depends on the acumen of the person filling it out. Second, “heart disease” is an 
extremely broad characteristic and, while it narrows the field, it does little else to suggest a 
phenotype. Third, heart disease is common in the general population, so these statistics suggest 
an association between HD and the heart where none may actually exist. In fact, the authors of 
the original death certificate analysis reported that, despite accounting for a significant proportion 
of deaths, heart disease was not reported more frequently in patients dying with HD; they 
therefore postulated that incidence of heart disease is similar between HD and unaffected 
populations (40). The findings I present in this thesis support that conclusion. Contrary to reports 
of inherent pathological processes in other mouse models (37, 83-86), I found no evidence of 
pathology in hearts from N171-82Q and zQ175 mice relative to WT in the absence of stress. My 
work thus centers on understanding the markedly smaller hearts in HD mouse models, a finding 
consistent with the only published study to date that examined the post-mortem heart in HD 
patients (46) and replicated by many HD mouse models (37, 84, 86).  
My studies showed that mTORC1, a master regulator of growth and metabolism, is 
dysregulated in HD mouse hearts starting at an early time point and continuing throughout 
disease. Consequently, I found that this diminished mTORC1 activity restricts adaptive cardiac 
hypertrophy in HD mice, underlying the pathologic processes that ensue in response to stress. 
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These observations, then, may subtly change the interpretation of the death certificate statistics: 
the important conclusion may not be that HD is associated with heart disease, but rather that HD 
is associated with death from heart disease. Future epidemiologic studies focusing on the heart in 
HD should explore this distinction and seek to establish the incidence and prevalence of heart 
disease among the HD patient population. More specifically, research should investigate the 
length of time between onset of heart disease and death in HD patients compared to unaffected 
relatives. Additionally, clinical studies should be designed to recruit HD patients diagnosed with 
heart abnormalities and follow them longitudinally to gain a clearer understanding of how heart 
disease progresses in HD patients vs. an unaffected, age-, sex-, and BMI-matched individual. 
In the experiments I report here, cardiac stress is associated with poor survival in HD 
mouse models. Conversely, regular exercise not only improves numerous psychosocial metrics 
for HD patients, it is also one of the few interventions to consistently show therapeutic 
effectiveness for improving motor function, gait, and balance (174). Both the cardiac stress model 
I induced and exercise-related stress are mediated by adrenergic signaling (157), but the crucial 
difference between the two is timing. Chronic adrenergic stimulation typically only occurs in 
response to an underlying pathology such as systemic hypertension or valvular stenosis, whereas 
exercise-related stress is acute, sporadic, and rarely causes maladaptive changes (157). 
Additionally, regular exercise is associated with decreased frequency of cardiovascular diseases 
characterized by chronic stress, such as coronary artery disease or hypertension (175). Thus, HD 
patients who exercise regularly would be expected to not only experience the neurologic and 
psychosocial benefits, but also be protected from potentially serious cardiovascular conditions. 
As discussed throughout this thesis, the cell-autonomous effect of mHTT expression in 
peripheral tissues is difficult to separate from abnormal neuronal inputs. Though certain 
peripheral systems such as the liver and immune system are capable of exerting some influence 
over brain physiology (172), nervous tissue is classically isolated from systemic conditions. Thus, 
the cell-autonomous effects of mHTT in the CNS are well-established. However, nearly every 
other tissue in the body receives some form of input from the brain, and thus identifying where a 
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particular peripheral phenotype originates is more difficult. The work I present in Chapter 3 
attempts to conclusively determine the necessity and sufficiency of mHTT expression for cardiac 
mTORC1 dysregulation. I was able to show that mHTT is necessary for the phenotype, but due to 
relatively low levels of overexpression I was not able to conclude if it was sufficient or not. With 
these data it is thus impossible to know how much of the phenotype relies on altered neuronal 
inputs. Multiple approaches could be taken to address the technical concerns with the 
experiment—including using a stronger promoter, incorporating enhancer elements, or changing 
the virus serotype—but even with the best transduction system, efficiency will be less than 100% 
and therefore not a perfect replica of a transgenic animal. It would thus be of great benefit to the 
community that engage in research on peripheral HD phenotypes to engineer a set of mice that 
allows conditional tissue-specific expression or knockout of a mHTT transgene or allele. These 
models could help to conclusively determine which phenotypes result from neurodegeneration 
and which result from cell autonomous effects in any number of peripheral tissues, and would 
thus help to direct potential therapeutics seeking to correct these abnormalities. 
Restoration of cardiac mTORC1 by caRheb transduction in N171-82Q mice restored 
adaptive hypertrophy in response to stress and mimicked the WT response. Consequently, mice 
expressing cardiac caRheb experienced only limited fibrosis and mortality. However, using 
caRheb to activate mTORC1 is employed here only as an experimental proof-of-concept 
technique and should not be considered a potential therapy for treating an HD heart phenotype. 
Constitutively activating mTORC1, as might occur through a genetic approach, was obviously 
beneficial to HD mice in the short term, but it has a myriad of potential long-term complications 
including cardiac rhabdomyoma, arrhythmia, and heart failure (176). The most ideal therapeutic 
strategy in HD is, of course, to treat the root cause by decreasing levels of mHTT, regardless of 
tissue type (2). But because tissue-specific gene delivery is challenging, and the HD heart 
phenotype seems to be relatively benign except under stress circumstances, a small molecule 
approach may be a very viable option.  
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Small molecule inhibitors of mTORC1 are abundant, specific, and used often in clinical 
settings as immunosuppressive and antineoplastic agents. On the other hand, mTORC1-specific 
activators are considerably less-common, and none are clinically-approved. (Considering the 
narrow set of clinical scenarios in which increased mTORC1 activity might be beneficial, this lack 
of resources is understandable.) Hence, this work provides justification for drug discovery and 
preclinical testing of new molecules that promote mTORC1 signaling. Another intriguing 
possibility is either oral leucine or BCAA supplementation, a treatment regimen that has been 
shown to augment mTORC1 activity in skeletal muscle biopsies from healthy volunteers (177). 
However, the utility of this therapy for HD patients depends on the mechanism of mTORC1 
dysregulation. Intraperitoneal injections of BCAA cocktail over a six week period did not 
significantly increase P-S6 or P-4EBP1 levels in HD mice. While further follow-up is needed to 
confirm these results, Rheb mislocalization may explain the lack of a robust effect. Intracellular 
nutrient sensors respond to ample BCAA levels by recruiting inactive mTORC1 to 
endomembranes, where it would normally come into contact with Rheb and become activated 
(109). However, if Rheb is mislocalized, as was observed in later-stage N171-82Q mouse hearts, 
BCAA supplementation would have little effect (148). A third possible therapeutic strategy is to 
identify and target the pathways regulated by mTORC1 that contribute most to the adaptive 
hypertrophic stress response. This approach has the benefit of increased specificity and reduced 
adverse effects, a particularly attractive quality considering the large number of mTORC1 targets. 
In conditional cardiac mTor knockout mice, deletion of 4ebp1 rescued most of the mortality and 
pathologic heart phenotype, suggesting that global protein synthesis is the key mTORC1 effector 
in adaptive hypertrophy (121). Thus, developing and testing a 4EBP1 inhibitor is an interesting 
possibility to attempt to restore proper stress compensation in HD hearts. However, if a large 
number of pathways are required for proper stress compensation, transiently increasing activity of 
mTORC1 may be the better option. 
Collectively, this work establishes a novel link between HD, mTORC1, and adaptive 
cardiac hypertrophy. The model that I propose herein is that cardiac mHTT expression 
dysregulates mTORC1 activity in HD hearts, either through impaired PI3K/Akt/mTOR axis 
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activation or through Rheb mislocalization depending on the disease stage, and this consequently 
impairs adaptive heart hypertrophy leading to increased mortality and pathology in response to 
stress. Ideally, future work will continue to characterize the cardiac phenotype in HD patients, 
establish the role of mHTT expression in cardiomyocytes and how it leads to dysregulated 
mTORC1, and develop therapeutic strategies to prevent mortality from heart disease HD patients. 
These advances, together with increased understanding of other peripheral HD phenotypes, will 
ensure that HD symptoms are well-managed once CNS-directed therapies are approved.  
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